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Summary 
 
Sleep is ubiquitous among species. Despite this known fact, the behavioral 
characteristics of sleep and wake are very diverse and species dependant. Sleep 
behavior manifests itself in many different ways, such as having only one eye 
closed during sleep (duck), having only one hemisphere in deep sleep at one 
time (dolphin), having an apnoea during the sleep period (seal), sleeping at 
different times of the day as seen in nocturnal species (bat), having a polyphasic 
sleep pattern (mice), or finally, the monophasic sleep pattern that characterizes 
normal human sleep. Although much remains unknown about the function of 
sleep, we believe that sleep must serve a vital function since it was conserved in 
evolution. Therefore, sleep may be essential for the existence of all creatures. 
 
This work focuses on sleep-wake regulation in humans. The study of sleep is of 
great interest since we are not able to influence consciously the characteristics of 
this state. Sleep is a state of diminished awareness and reduced responsiveness. 
 
The complexity of sleep makes it an interesting topic of investigation. Sleep 
states, sleep architecture, sleep timing and duration, and sleep homeostasis are 
only a few aspects which can be examined. The different characteristics of brain 
waves during sleep and wakefulness are of great importance in sleep research.  
 
Delta activity is a marker of the sleep electroencephalogram on which the well-
known and widely accepted two-process-model of sleep-wake regulation is 
based. The model hypothesizes that the timing and duration of sleep and waking 
are the result of two interacting processes. The homeostatic process is 
dependant on the prior duration of wakefulness, whereas the circadian process is 
driven by the suprachiasmatic nucleus in the hypothalamus. In addition, the 
synaptic homeostasis hypothesis, which posits that wakefulness is associated 
with synaptic potentiation and sleep is associated with synaptic downscaling, 
served as the theoretical foundation of this thesis. 
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The aim of this project was to study the mechanism of the homeostatic process 
of sleep on a cellular level by studying the effects of sleep deprivation on 
metabotropic glutamate receptor subtype 5 (mGluR5) in healthy volunteers. 
Further, We studied the homeostatic process on a physiological level in patients 
with idiopathic hypersomnia (IH). We challenged healthy subjects and patients 
with a period of 40h of prolonged wakefulness. 
 
The first project of this thesis (Chapter 2) focuses on the effect of prolonged 
wakefulness and the availability of mGluR5 in healthy male volunteers, and on 
possible associations with cognitive functions. This positron emission 
tomography (PET) study was conducted in a randomized, crossover fashion with 
the highly selective radioligand 11C-ABP688. Twenty-two male volunteers 
completed the study, including one control PET scan after 9 hours awake and a 
sleep deprivation scan after 32 hours of wakefulness (i.e., after spending one 
night without sleep). The main finding of this study was a global increase in 
mGluR5 availability after one night without sleep. In addition, a significant 
increase was measured in six regions of interest that were previously suggested 
to be involved in sleep-wake regulation. The increase in mGluR5 availability was 
positively correlated with increase in subjective sleepiness. 
 
The second project of this thesis (Chapter 3) aimed to gain a broader 
understanding of the pathophysiology of IH. By keeping patients with IH awake 
for 40 hours, we examined homeostatic and circadian aspcects of sleep-wake 
regulation in these patients. The study was conducted in a matched-pair design 
with healthy controls. Visually scored sleep states were not statistically different 
between the two groups in baseline and recovery nights. In addition, non-rapid 
eye movement sleep (NREMS) episode analysis revealed a similar time course 
in δ-power decay (0.75-4.5 Hz) in IH patients and healthy volunteers. Never-
theless, we found differences between the groups in EEG θ-/α-, σ- and β-activity. 
Patients with IH had a significant decrease in power compared to controls in 
NREMS and REMS. During prolonged wakefulness, the EEG revealed 
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decreased β-activity in IH patients when compared to controls in all waking EEG 
recordings (i.e., across all time points). EEG β-activity is hypothesized to reflect 
brain arousal, attention, alertness, and reactivity. Decreased β-activity could 
indicate insufficient arousal levels and provide a physiological measure of 
daytime sleepiness in IH patients. During the 40 hours awake, patients with IH 
rated themselves as sleepier than controls, and the largest difference was seen 
within the first 16h awake. Neurobehavioral performance data revealed a similar 
picture. Patients performed worse during the sleep deprivation period than 
controls with a maximal deviation during the first 16h awake.  
 
In conclusion, we studied for the first time a role for mGluR5 in relation to sleep 
and extended wakefulness. We observed increased mGluR5 availability after 
prolonged wakefulness, which correlated positively with sleepiness. These 
results may indicate that this receptor could present a potential drug target for the 
treatement of excessevie sleepiness. The second project was the first sleep 
deprivation study performed in IH patients. It revealed normal sleep-wake 
regulation in IH patients, yet a deficient brain arousal system during wakefulness. 
This finding provides a rational basis for clinicians to study more extensively 
daytime functions in patients with IH in the future. 
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Zusammenfassung 
 
Schlaf ist ein allgegenwärtiges Phänomen unter den Tieren. Die Charakteristiken 
des Schlaf- und Wachverhaltens können je nach Art sehr unterschiedlich sein. 
Das Schlafverhalten reicht von nur einem Auge geschlossen halten (Ente), nur 
eine Hirnhälfte im Schlafzustand haben (Delphin), Apnöen in Atemmuster 
aufweisen (Robbe), ein nachtaktives Verhalten ausüben (Fledermaus) oder einen 
polyphasischen Schlafrhythmus aufweisen (Maus) bis hin zum monophasischen 
Schlafmuster des Menschen. Obwohl vieles über die Funktion des Schlafes noch 
verborgen ist, wissen wir, dass der Schlaf eine wichtige Funktion erfüllt. Er hat 
die Evolution überstanden und scheint demzufolge eine lebenswichtige Funktion 
auszuüben. 
 
Diese Arbeit erforscht die Schlaf-Wachregulation beim Menschen. Den Schlaf zu 
untersuchen ist von hohem Interesse, weil wir die Charakteristiken dieses 
Zustandes nicht bewusst beeinflussen können. Schlaf ist ein Zustand mit 
vermindertem Bewusstsein und reduzierter Reaktionsfähigkeit. 
 
Es ist interessant, die Komplexität des Schlafes zu untersuchen. Schlafstadien, 
die Schlafarchitektur, der Zeitpunkt des Schlafs, die Schlafdauer und die 
Schlafhomöostase sind nur einige Aspekte, die studiert werden können. Die 
unterschiedlichen Merkmale der Hirnwellen und deren Generierung im Gehirn 
während des Schlaf- und Wachzustandes sind von grosser Wichtigkeit in der 
Schlafforschung. 
 
Die δ-Aktivität ist ein Merkmal des Schlaf-Elektroenzephalograms, auf welcher 
das bekannte und weitherum akzeptierte Zwei-Prozess Modell der Schlaf-
Wachregulation beruht. Dieses Modell besagt, dass der Zeitpunkt und die Dauer 
des Schlafs und der Wachheit das Resultat zweier interagierender Prozesse 
darstellen. Der homeostatische Prozess ist von der Dauer der vorangegangenen 
Wachzeit abhängig. Dagegen ist der zirkadiane Prozess endogen reguliert, über 
  
  VIII 
die suprachiasmatischen Kerne im Hypothalamus. Das Modell der synaptischen 
Homöostase liefert eine mögliche zelluläre Erklärung des homöostatischen 
Prozesseses und diente zusätzlich als theoretische Basis für meine Arbeit. 
 
Das Ziel meiner Arbeit war, einen möglichen Mechanismus des 
homöostatischen Prozesses auf molekularer Ebene zu untersuchen. Dazu 
studierten wir die Rolle des metabotropen Glutamat-Rezeptors des Subtyps 5 
(mGlu5 Rezeptoren) bei gesunden Probanden. Desweitern habe ich den 
homöostatischen Prozess auf einer physiologischen Ebene bei Patienten mit 
idiopathischer Hypersomnie studiert. Wir haben den homöostatisch regulierten 
Schlafdruck bei gesunden und kranken Probanden durch die Verlängerung der 
Wachzeit bis 40 Stunden experimentell erhöht. 
 
Das erste Projekt meiner Arbeit (Kapitel 2) befasst sich mit dem Effekt von 
Schlafentzug auf die Ausprägung der mGlu5 Rezeptoren bei gesunden 
männlichen Versuchspersonen und einer möglichen Assoziation mit kognitiven 
Funktionen. Diese Positron Emissions Tomopgrahie (PET) Studie wurde mit dem 
hoch selektiven Radioliganden 11C-ABP688 in einem randomisierten und 
überkreuzten Ablauf durchgeführt. Zweiundzwanzig freiwillige Männer haben das 
Studienprotokoll vollständig durchlaufen. In der  Kontrollbedingung wurde die 
PET Messung nach 9 Stunden Wachzeit durchgeführt. In der 
Schlafentzugsbedingung wurde die PET Messung nach 32 Stunden Wachzeit, 
beziehungsweise nach einer Nacht ohne Schlaf, durchgeführt. Die Studie hat 
gezeigt, dass eine Nacht ohne Schlaf die mGlu5 Rezeptor-Verfügbarkeit im 
Gehirn global ansteigen lässt. In 6 vorgängig festgelegten Regionen (regions of 
interest), welchen in früheren Studien wichtige Rollen bei der Schlaf-
Wachregulation zugeschrieben wurden, konnte eine Erhöhung gemessen 
werden. Die Zunahme korrelierte positiv mit der Zunahme der subjektiven 
Schläfrigkeit nach Schlafentzug. 
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Das zweite Projekt meiner Arbeit (Kapitel 3) versuchte ein besseres Verständnis 
der Pathophysiologie der idiopathischen Hypersomnie (IH) zu erlangen. Indem 
wir Patienten mit IH 40 Stunden wach hielten, konnten wir Aspekte der 
homöostatischen und zirkadianen Prozesse untersuchen. Diese Studie wurde in 
einer gepaarten Anordnung mit gesunden Kontrollpersonen durchgeführt. Die 
visuell definierten Schlafstadien unterschieden sich weder in der Baselinenacht 
noch in der Erholungsnacht zwischen den beiden Gruppen. Des weiteren wurde 
in beiden Gruppen im non-rapid eye movement Schlaf (NREMS) ein ähnlicher 
Verlauf des Abfalls der δ-Aktivität beobachtet. Dennoch haben wir im EEG einen 
Unterschied im Bereich der θ-/α-, σ- und β-Frequenzen festgestellt. Patienten mit 
IH hatten im NREMS und REMS eine erniedrigte Leistungsdichte im Vergleich zu 
den gesunden Kontrollen. Auch während der verlängerten Wachzeit, zeigten alle 
Wach-EEG Messungen im Vergleich zu den Kontrollen bei den Patienten mit IH 
eine reduzierte β-Aktivität. Es wird vermutet, dass die β-Aktivität im EEG den 
Wachheitszustand des Gehirns, Aufmerksamkeit, Wachheit und 
Reaktionsbereitschaft widerspiegelt. Die reduzierte β-Aktivität könnte den zu 
geringen Wachheitszustand des Gehirns anzeigen, und ein physiologisches 
Merkmal der erhöhten Tagesschläfrigkeit darstellen. Während den 40 Stunden 
Wachheit, haben sich die Patienten schläfriger eingeschätzt als die gesunden 
Kontrollen. Die grösste Differenz konnte während den ersten 16 Stunden 
beobachtet werden. Die Daten der anhaltenden Aufmerksamkeit zeigten ein 
ähnliches Bild. Die Resultate eines validierten Reaktionstests zeigten während 
der ganzen Wachzeit eine schlechtere Leistung bei den Patienten im Vergleich 
zu den Kontrollen mit einer maximalen Divergenz während den ersten 16 
Stunden nach dem Erwachen. 
 
Meine Arbeit untersuchte zum ersten Mal einen möglichen Zusammenhang 
zwischen der Verfügbarkeit von mGlu5 Rezeptoren und Schlafentzug. Wir haben 
nach verlängerter Wachzeit eine klare Erhöhung der Rezeptorverfügbarkeit 
festgestellt, welche mit der subjektiven Schläfrigkeit positiv korrelierte. Dieser 
Befund könnte auf eine mögliche neue Zielstruktur für die pharmakologischen 
  
  X 
Behandlung von erhöhter Tagesschläfrigkeit hindeuten. Das zweite Projekt war 
die erste Schlafentzugsstudie bei Patienten mit IH. Sie zeigte eine normale 
Schlafregulation; dagegen war der Wachheitszustand des Gehirns am Tag 
reduziert. Dieses Resultat legt nahe, sich in Zukunft mehr auf das Studium der 
Wachfunktionen bei Patienten mit IH zu verlegen. 
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Abbreviations 
 
11C-ABP688  3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O- 
 11C-methyl-oxime 
A2AR Adenosine A2A receptor 
AAS Ascending arousal system 
ACC Anterior cingulate cortex 
Ach Acetylcholine 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BDNF Brain-derived neurotrophic factor 
B/I Bolus-infusion 
BL Baseline night 
BF Basal forebrain 
BP Binding Potential 
Ca Calcium 
CNS Central nervous system 
D2 D2 Dopamin receptor 
DV Distribution volume 
DVnorm Normalized distribution volume 
ECG Electrocardiogram 
EDS Excessive daytime sleepiness 
EEG Electroencephalogram 
EMG Electromyogram 
EOG Electrooculogram 
ESS Epworth sleepiness scale 
FFT Fast fourier transformation 
FMR1 Fragile mental retardation protein 1 
fMRI Functional magnetic resonance imaging 
FXS Fragile X syndrome 
GABA γ-aminobutyric acid 
GLU Glutamate 
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GluR Glutamate receptor 
Gy Gray (Unit) 
Hcrt / Orx Hypocretin / Orexin 
ICSD-2 International criteria of sleep disorder 2nd edition 
IH Idiopathic hypersomnia 
IP3 Inositol triphospaht  
KSS Karolinska sleepiness scale 
LC Locus coeruleus 
LDT Laterodorsal tegmental nuclei 
LHA Lateral hypothalamus 
LTD Long-term depression 
LTP Long-term potentiation 
Mg Magnesium 
mGluR Metabotropic glutamate receptor 
mGluR1/5 Metabotropic glutamate receptor subtype 1/5 
MRI Magnet resonance imaging 
MT Movement time 
μV microvolt 
NA Noradrenalin 
NC Narcolepsy 
NMDA N-methyl-D-aspartate 
NREM Non-rapid-eye-movement  
PET Positron emission tomography  
PFC Prefrontal cortex 
PLC Phospolipase C 
PLMS Periodic leg movement of sleep 
PK Protein kinase 
PMOD Pixel-wise image modeling 
POMS Profile of mood state 
PPT Pedunculopontine tegmental nucleus 
Process C Circadian process of the two process model 
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Process S Homeostatic process of the two process model 
PSG Polysomnography  
PVT Psychomotor vigilance task 
REC Recovery night 
REM Rapid-eye-movement 
RF Reticular formatio 
RL REM latency 
RT Reaction time 
S1 - 4 Sleep stage 1 - 4 
SD Sleep deprivation 
SCN Suprachiasmatic nucleus 
SL Sleep latency 
SOREMS Sleep onset REM sleep 
STAI State trait anxiety inventory 
SUV Standard uptake value 
SWA Slow-wave activity 
SWS Slow wave sleep 
TAC Time activity curve 
TMN Tuberomammillar nucleus 
TPQ Tridimensional personality questionnaire 
TST Total sleep time 
VLPO Ventrolateral preoptic nucleus 
VOI Volume of interest 
W Wake 
WASO Wake after sleep onset 
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Chapter 1 
 
Introduction 
 
1.1  The brain as a bioelectric generator  
 
The human brain is a complex organ where thousands of interacting processes 
occur at the same time. The signals coming from the brain influence different 
aspects of human metabolism and physiology, one of which is sleep-wake 
regulation. The brain can be seen, beside its many other functions, as a 
bioelectric generator. Whereas an electric generator is transforming kinetic 
energy into electrical energy, the brain is transferring chemical cell currents into 
cell dipoles, which lead to an electrical field. These cortical electrical fields can be 
measured with the non-invasive method of electroencephalography (EEG). The 
inventor of this method was the German psychiatrist Hans Berger from Jena who 
accomplished the first human recordings, typically on his children, in the 1920’s 
(Berger, 1929). To measure the EEG, at least two surface electrodes are needed 
which record the potential difference between them. One is the reference 
electrode, and the other is the electrode where the local signal is measured. The 
usage of several electrodes makes it possible to study topographic aspects of 
brain waves. The correct placement of the electrodes is defined in the 10-20 
system, invented 50 years ago by Herbert Jasper (Jasper, 1958). Electrodes are 
placed at well-defined inter-electrode distances of 10% and 20% over frontal, 
parietal, occipital, and temporal regions of the scalp (Fig. 1). 
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Figure 1: The original figure illustrates the international 10-20 system (Jasper 1958). 
Please note that the electrodes are erroneously located inside the skull on the surface of the 
cortex. 
 
Three vigilance states can be distinguished in human beings: Wakefulness, non-
rapid-eye-movement sleep (NREMS), and rapid-eye-movement sleep (REMS). In 
the wake state, when a person is fully conscious, the rather high frequency α-
activity is dominant, and towards deep sleep the low frequency and high 
amplitude δ-activity becomes prominent. NREMS and REMS are conditions of a 
reduced state of consciousness and cannot be influenced voluntarily by a 
sleeping person. 
 
The waking electroencephalogram  
It is assumed that the rhythmic activity measured in the EEG represents cellular 
feedback loops between deep brain structures (e.g., thalamus) and cortical 
regions. The better these feedback loops become integrated and interconnected 
with other brain areas, the faster the frequency of EEG oscillations will be 
(Klimesch, 1999). Each brain wave can be decomposed into distinct amplitudes 
and frequencies which are assigned to different frequency bands. The most 
commonly used nomenclature in wakefulness is δ, θ, α, β and γ (Niedermeyer, 
2005). The frequency bands definition in wakefulness varies between studies. 
One study specified these bands with the frequencies < 3.5 Hertz (Hz) as δ, 4-
7.5 Hz as θ, 8-13 Hz as α, 14-30 Hz as β, and > 30 Hz as γ  (Niedermeyer, 
2005). The most prominent rhythmic activity during relaxed wakefulness is the α-
wave. When a person closes his/her eyes, the amplitude of this wave becomes 
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larger and is seen best in occipital regions. A hallmark of the α-activity is its 
dropout with the earliest approach of drowsiness. From a topographical point of 
view, faster rhythms are present in posterior regions, whereas the slower waves 
are more prominent on anterior sides. Age is suggested to play a role in the 
modulation of the α-activity. The acceleration is thought to end around the age of 
ten, and tends to show little or no decline in elderly subjects. This decline is a 
result of age related neurological diseases, or even a lack of mental training in 
later life, rather than an effect of age per se (Klimesch, 1999; Niedermeyer, 
2005). Different studies show a relation between α-activity and cognitive 
performance, reaction time, intelligence, or stress and anxiety. Even though the 
amplitudes vary considerably from individual to individual and, within a person, 
from moment to moment, there is evidence that body temperature, menstrual 
cycle and genetic background of a person modulate the shape of the α-frequency 
(Bodenmann et al., 2009b). A twin study reports a high heritability of 89% and 
states the rhythmic brain-electrical activity as one of the most heritable 
characteristics in humans (van Beijsterveldt et al., 1996). It can be assumed that 
there are cortico-cortical and thalamo-cortical systems which interact in the 
generation of cortical α-rhythms (Steriade et al., 1990). In addition, the β-activity 
is thought to represent an important physiological marker. The β-rhythm was 
discovered by Berger in 1930, and is most prominent over frontal and central 
regions. Beta-activity seldomly exceeds an amplitude of 30 μV (Klimesch, 1999; 
Niedermeyer, 2005). A gender difference was found by Matsuura, suggesting 
that females have more prominent β-activity than males (Matsuura et al., 1985). 
Walter and Dovey (Walter and Dovey, 1944) introduced the θ-activity which is 
better seen in children than in adults (Klimesch, 1999; Niedermeyer, 2005). In 
animals the θ-rhythm represents a prominent sinusoidale waveform generated in 
the hippocampus and has wide frequency range (3-12 Hz) and high power. A 
crucial finding is that with increasing cognitive demands, especially in memory 
tasks, short-term memory demands lead to θ synchronization (increase in band 
power), whereas long-term memory demands lead to task specific 
desynchronization (decrease in power) in the upper α band (Klimesch, 1996). 
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Increased sleepiness was referred to increased θ-activity and lower α-activity 
(Cajochen et al., 1995; Aeschbach et al., 1997). Furthermore, hippocampal θ-
activity is thought to be important in the induction of long-term potentiation (LTP), 
and is suggested to be related to the encoding of new information in a similar 
way to LTP (Kamondi et al., 1998; Tsanov and Manahan-Vaughan, 2009). 
  
Brain waves during sleep and their classification 
Sleep is neither a passive nor a continuous state. Sleep is an active condition 
with region and network specific brain activity. Sleep is a cyclic alternation 
between NREMS and REMS (Aserinsky and Kleitman, 1953; Dement and 
Kleitman, 1957; Borbély and Achermann, 2005). Nocturnal sleep can be roughly 
divided into four to five consecutive NREMS/REMS cycles with durations of 
approximately 90 to 120 minutes (Feinberg and Floyd, 1979).  
The sleep EEG can be quantified by the differentiation of the brain waves into 
amplitude and frequency. This information, together with the electroocculogram 
(EOG) and electromyogram (EMG) signals, is used to assign the brain waves 
into specific sleep stages. In the late 1960’s, the manual of standardized 
terminology was published by Rechtschaffen and Kales (Rechtschaffen and 
Kales, 1968). They distinguish between six states: Wakefulness (W), Movement 
time (MT), Stages 1 to 4 (S1-S4), and REMS. NREMS is the sum of epochs 
scored with S1, S2, S3 and S4. The characterization of wakefulness is, as 
already mentioned, the dominant α-activity and/or mixed frequency activity and 
low power (Fig. 2A). Movement time occurs when a person changes his/her 
position in bed. The EMG signal is recorded by placing two electrodes beneath 
the chin. This raw signal shows high amplitude activity, and the EEG and EOG 
signals show, as a result, movement artifacts. Muscle twitches often occur in S1 
while falling asleep. Nocturnal sleep is normally initiated by S1, which is the 
transient state between wakefulness and sleep. When a subject falls asleep, 
rolling eye movements occur and the EEG typically shows θ-waves with mixed-
frequency activity and low power. Stage 2 indicates two distinct features called 
sleep spindles (11-15 Hz) and K-complexes. A sleep spindle is defined by 
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duration of at least 0.5 seconds. The shape is given by waxing and waning 
amplitudes of 6 to 7 distinct waves within one spindle. K-complexes are shaped 
by a negative half wave followed by an even bigger positive half wave (Fig. 2B). 
The amount of S2 epochs is increasing towards the end of the night, and is the 
most frequently occurring sleep state with around 55% of total sleep time. Stages 
3 and 4 are often taken together and are referred to as deep sleep, or slow-wave 
sleep (SWS). The physiological correlates are the slow oscillation with 
frequencies < 2 Hz and peak-to-peak amplitude > 75 μV (Fig. 2C). A discrete 
change in EOG and EMG signals is seen from the transition of NREMS to 
REMS. REMS was identified and defined by Eugene Aserinsky and Nathaniel 
Kleitman in the early 1950’s (Aserinsky and Kleitman, 1953). The eye 
movements occur in all directions and are binocularly synchronous (Dement and 
Kleitman, 1957). The EMG signal shows a gradual diminution as sleep 
approaches, and is essential to clearly assign the REMS stage. A typical feature, 
even though not shown by all subjects, is the muscle twitch shown by a single 
peak in the EMG signal. For a long time, it was believed that REMS is the 
dreaming phase. But in 1957, Dement and Kleitman (Dement and Kleitman, 
1957) suggested, and partially clarified, that dreaming can occur in all sleep 
stages and is not restricted to REMS. The behavioral features of REMS are low 
muscle tone, also referred to as muscle atonia, and is controlled by glutamatergic 
and glycinergic projections into the spinal cord (Siegel, 2004), and saccadic eye 
movements (Fig. 2D). The EEG frequency and amplitude are similar to S1 with 
the exception that no vertex sharp waves occur, and sleep spindles and K-
complexes are absent. While at sleep onset in the evening (when entrained), the 
propensity for NREMS is high and for REMS low, the propensities are practically 
equal by the end of the sleep period. Furthermore, REMS modulates 
physiological markers such as heart rate or blood pressure (Somers et al., 1993). 
In contrast to deep slow-wave sleep (S3+S4; SWS), REMS becomes more 
prominent in the second half of the night. 
As illustrated above, sleep reflects a cycling alternation between NREMS and 
REMS. Sleep architecture can be visualized by a hypnogram. A hypnogram (Fig. 
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3) is generated by assigning one sleep stage to each 20- or 30-second epoch of 
the night. An epoch is a short time window, usually lasting 20 or 30 seconds, of 
recorded brain activity. A typical night of sleep (e.g., 8 hours) will be split up into 
1440 epochs which need to be manually scored. Even though this scoring 
procedure is based on arbitrary criteria, it was shown to have high interrater 
reliability (Danker-Hopfe et al., 2009). Nevertheless, a better and more accurate 
approach was needed to quantitatively analyze the sleep EEG. This was 
achieved by calculating the power spectrum of the night (Section 1.2). The slow-
wave activity (SWA) 0.5-4.5 Hz is a correlate of SWS, and is referred to as a 
marker of sleep propensity; it therefore reflects the homeostatic process S (see 
Section 1.3) (Borbély, 1982; Cajochen et al., 1999; Finelli et al., 2001b; Borbély 
and Achermann, 2005) and shows a dynamic decline with respect to time spent 
asleep (Fig. 3).  
In the last few years, several studies indicated that the EEG signal is ‘trait-like’ 
and can be seen as an individual physiological fingerprint. A study in 
monozygotic (MZ) and dizygotic twins (DZ) showed a high heritability in the δ-
range and the spindles (Ambrosius et al., 2008). Monozygotic twins showed a 
higher within-pair resemblance in spectral power than DZ, which reflects the high 
heritability of this phenotype. Another twin study showed a heritability in the 8-16 
Hz range of 96% (De Gennaro et al., 2008); Finelli showed that even the 
topographical feature in the EEG shows a fingerprint-like manner and may reflect 
individual traits of functional anatomy (Finelli et al., 2001a). 
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Figure 2: Electrical raw signal in the three vigilance states. A The waking EEG typically shows 
mixed frequency activity and low amplitude brain waves with a prominent occurrance of α-waves 
(8-12 Hz). Eye blinks are indicated by a spike in the EOG. The muscle tone is rather high. B 
Stage 2, NREM sleep, has two recurrent features named the K-complexes and the sleep spindles 
(11-15 Hz) on a mixed frequency and low-voltage background. C Stage 4, NREMS, refers to 
deep sleep with the hallmark of low frequency (0.5-4.5 Hz), high amplitude slow waves. The EMG 
is low, reflecting a physiological relaxed state. D REMS, shows the distinct properties of random 
saccadic eye movement and a very low muscle tone reflecting muscle atonia. EEG signal shows 
mixed frequency, low voltage and amplitude. 
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Figure 3: Hypnogram and slow-wave activity in a healthy subject. Upper panel: Manually scored 
sleep stages during an 8-hour sleep opportunity. R: REMS, W: Wake, 1-4: Sleep stage 1-4, M: 
Movement time. Lower panel: The corresponding slow-wave activity (0.5-4.5 Hz) shows a 
decreasing trend across the night. 
 
 
1.2  The quantification of the electroencephalogram 
 
In a physiological sense, EEG power reflects the number of neurons that 
discharge synchronously. The raw signal is made up of two variable entities: The 
amplitude (microvolt/μV), and the frequency (Hz) which is displayed against time. 
The amplitude of the EEG, when measured with depth brain electrodes, lies 
between 500-1500 μV, and attenuates the further away from the signal 
generating cells the recording takes place. The amplitude of the EEG is about 
10-100 μV when measured on the scalp (Aurlien et al., 2004).  
 
Brain activity is recorded with a specific frequency rate; it is filtered, digitized and 
transmitted to a computer where the signal is stored. 
Artefacts are visually identified and excluded before the raw signal undergoes a 
Fast Fourier transformation (FFT) procedure. The FFT is a mathematical 
approach to quantify the EEG raw signal. Most often, the bipolar derivation C3A2 
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is used for this procedure (Cooley and Tukey, 1965). If topographical analyses 
are performed, additional derivations undergo FFT. An all-night power spectrum 
is generated by the FFT for each 20-seconds time window in MATLAB (The 
MathWorks, Natick, MA). The principle of the FFT is a decomposition of the raw 
signal into different amplitudes and frequencies per time window. The time 
window is short (4s in sleep, 2s in wake), in order to have a stationary signal 
which is a prerequisite of FFT (Achermann, 2009). The resolution is the inverse 
of the length of the analysed epoch (0.25 Hz in sleep, 0.5 Hz in wake). In short, 
the algorithm transforms the digitised EEG signal from the time domain into the 
frequency domain. In Figure 4, the characteristic power spectrum of NREMS, 
REMS and wakefulness are illustrated. 
 
Figure 4. Spectral characteristics of the EEG (C3A2 derivation) in NREMS, REMS and rested 
wakefulness. NREMS is characterised by dominant rhythmic activity in low frequencies resulting 
in high power, and a second peak in the σ-range. REMS, in contrast, has a gradual decrease in 
power with increasing frequency. Wakefulness has highest power < 1 Hz and a second maximum 
in the α-range. Moreover, β-power is higher in wakefulness compared to NREMS and REMS.  
NREMS (combined stages 1 to 4) and REMS: All-night power spectra of an 8-hour baseline night 
(00:00 – 08:00) in 22 healthy men (mean age ± SEM: 23.4 ± 0.5 years). Frequency resolution: 
0.25 Hz. Wakefulness: Average over four 3-min EEG recordings with closed eyes conducted at 
08:15, 11:00, 14:00 and 17:00 following the baseline night. Frequency resolution: 0.5 Hz. Data 
taken from the study performed by (Bodenmann et al., 2009a).  
NREMS 
REMS 
Wakefulness 
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1.3  The two process model of sleep wake regulation  
 
The established, widely accepted two-process model of sleep wake regulation 
(Fig.5) was postulated by the internationally well-known sleep researcher 
Alexander Borbély in 1982. It posits that the interaction of the homeostatic 
process (S) and the circadian process (C) generates the timing of sleep and 
waking (Borbély, 1982). The homeostatic process increases during wakefulness 
and declines during sleep. The process C is guided endogenously via the 
suprachiasmatic nucleus (SCN) in the hypothalamus. The pacemaker with only 
20000 neurons displays a periodicity of approximately 24 hours (Moore and 
Eichler, 1972; Stephan and Zucker, 1972), and modulates an upper and lower 
threshold (H and L) (Fig.6). The timing and termination of a sleep episode is, on 
the one hand, defined by these two thresholds and, on the other hand, by the 
intersection of curves S and C (Borbély, 1982; Achermann, 2004). 
 
 
Figure 5: Two-process model of sleep wake regulation. The interaction of process S and C 
determines the waking and sleep periods. After prolonged wakefulness the SWA will be 
enhanced in the subsequent recovery night compared to baseline night (Borbély, 1982). SWS: 
Slow wave sleep; SWA: Slow-wave activity; Process S: Homeostatic process; Process C: 
Circadian process. 
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Figure 6: Schematic representation of the two-process model of sleep regulation. Process S 
rises during waking and declines during sleep. Process C modulates the thresholds of H and L. 
Interaction of Process S with H and L determines the onset and termination of a sleep episode 
(Achermann, 2004). Process S: Homeostatic process; Process C: Circadian process, H: high 
threshold of circadian process; L: low threshold of circadiane process. 
 
It needs to be mentioned that sleep has an intensity dimension which is 
increased after prolonged wakefulness. The other characteristic of sleep is sleep 
duration, which also increases after prolonged hours awake (Borbély, 1982; 
Daan et al., 1984).  
 
Sleep intensity corresponds to the summation of S and C, and is therefore 
represented by the difference between S and C (Fig.5). The physiological marker 
of process S during the biological night is derived from the SWA, a correlate of 
the δ-activity, which shows an exponential decay during the night and may 
represent an intensity parameter of the sleep process. A possible physiological 
correlate of homeostasis during wakefulness is thought to be reflected by the 
power in the θ-/low α-frequency range. It was shown that increasing sleep need 
during prolonged hours awake leads to an enhancement in θ-/low α-band in the 
waking EEG (Cajochen et al., 1995; Aeschbach et al., 1997; Finelli et al., 2001b). 
It is assumed that the increase of θ-activity in the waking EEG during extended 
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wakefulness is closely related to the enhancement of SWA in recovery NREMS 
(Finelli et al., 2000). 
 
Mathematical modelling helps to delineate the processes involved in the 
regulation of sleep and neurobehavioral function, and offers thereby a conceptual 
framework for the analysis of existing and new data. Mathematical functions were 
fit to available data pools to estimate the build up of process S during 
wakefulness and its decay during sleep. It was hypothesized that process S is 
increasing according to an exponential saturating function during wakefulness, 
and is declining roughly exponentially during sleep (Achermann, 2004). It was 
first quantified on the basis of baseline data and recovery sleep after sleep 
deprivation (Daan et al., 1984). Further investigations proposed a non-linearity of 
the interaction of the two processes to predict wakefulness and neurobehavioral 
performance during the day, and to promote consolidated sleep throughout the 
night (Van Dongen et al., 2003). A robust method was established by Rusterholz 
et al. (Rusterholz et al., 2010) to estimate the process S on an individual basis. 
Process S was modelled for each person by a saturating exponential function 
during wakefulness and an exponential decline during sleep.  
 
Sleep deprivation (SD) is a useful tool to challenge and study sleep homeostasis. 
Partial or total SD leads to an increase in SWA in the subsequent night. 
Compelling evidence was presented in several studies that show how SWS and 
SWA increase as a function of prior hours spent awake (Webb and Agnew, 1971; 
Achermann and Borbély, 2003; Achermann, 2004). In addition, it has been 
shown that frontal regions are particularly sensitive to SD, thus leading to 
impairments in cognitive functions (Horne, 1993; Huber et al., 2000).  
Even though it is known that SWS and REMS have opposite trends in nighttime 
sleep, the results of sleep deprivation studies were rather surprising. As 
expected, SWS was enhanced in recovery sleep, whereas REMS was not 
altered, or in some instances even decreased. The rebound of SWS was mainly 
seen in the first recovery night (REC) by an increased δ-power (Agnew et al., 
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1967). In REMS deprivation studies, an increased REMS proportion, which was 
present for more than one night, was found in a recovery night (Dement, 1960; 
Dement, 1965; Moses et al., 1975).  
Another aid to explore and modulate process S is a nap protocol study. Naps are 
a useful tool to study the level of slow wave propensity after various durations of 
waking. Naps taken later in the day contain more SWS than naps taken earlier in 
the day (Maron et al., 1964; Achermann and Borbély, 2003). 
 
 
Figure 7: Schematic representation of the evolution of process S during 2-hour-nap and total-
sleep-deprivation protocols (Achermann, 2004). 
 
Not only do manipulations of time spent awake, or sleeping, lead to a change in 
process S, but genetic factors may also contribute to individual differences in 
vigilance states and therefore in sleep homeostasis (Rétey et al., 2005; Viola et 
al., 2007; Landolt, 2008a). 
 
Recently, a study has shown that the prominent occurrence or attenuation of 
distinct brain waves during sleep may reflect cerebral activity during wakefulness 
prior to sleep. For example, authors observed that sleep SWA reflecting 
synchroneous neuronal firing, was reduced over the sensorimotor cortex contra-
lateral to the arm which was immobilized during the day. These findings point to 
local aspects of sleep and sleep regulation (Huber et al., 2004; Huber et al., 
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2006). A study performed in neurosurgical patients showed similar findings (Nir 
et al., 2011). The simultaneous recording of scalp EEG, intra cerebral EEG, and 
unit firing showed that most sleep slow waves (< 1 Hz) and the underlying active 
and inactive neuronal states occur locally (Nir et al., 2011). It demonstrates that 
some brain areas are active while others are silent. A further study suggested 
that local sleep also occurs in awake rats. Neuronal ‘off’ periods are features 
occurring in sleep. The study showed that cortical neurons in rats, which were 
awake for long periods, can go locally ‘offline’, as detected by slow-waves in the 
EEG (Vyazovskiy et al., 2011). Although the exact mechanisms remain to be 
established, a considerable number of reports indicate that local activation of 
brain regions during wakefulness results in sleep EEG changes in these regions. 
This supports the hypothesis that local aspects of sleep regulation may reflect 
recovery or reactivation processes in brain areas that have been used during 
wakefulness (Benington and Heller, 1995). 
 
 
1.4  Physiological and cellular properties of synaptic plasticity 
 
“When an axon of cell A… excites cell B and repeatedly or persistently takes part 
in firing it, some growth process or metabolic change takes place in one or both 
cells such that A’s efficiency, as one of the cells firing B is increased.” 
(Donald Olding Hebb, 1949) 
 
Out of the prominent quotation of Donald O. Hebb the area of synaptic plasticity 
emerged. In short: Simultaneous activation of interconnected cells leads to 
modification of synaptic components and changes in gene expression, and is 
followed by pronounced increases in synaptic strength which is referred to as 
functional plasticity. 
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A further very well known statement by Hebb summarises the whole theory in 
just a few words. 
“Cells that fire together, wire together”  
Donald Olding Hebb 
1904 - 1985 
 
General overview 
Charles Scott Sherrington was the person who named the site of action which 
Donald O. Hebb described as ‘a synapse’. Synaptic plasticity is the ability of the 
connections between two neurons to change in strength in response to either use 
or disuse of transmission over synaptic pathways. Neuroscientists refer to the 
‘disuse’ as long-term depression (LTD), and to the ‘use’ as long-term potentiation 
(LTP). Long-term potentiation and LTD appear to be essential in the stabilization 
and elimination of synapses during the developmental fine-tuning of neural 
circuits and, therefore, lead to behavioural changes. One consequence of high 
interest is the belief that LTP is an underlying mechanism for learning and 
memory in vertebrates. 
 
Long-term potentiation was first described in 1973 by Tim Bliss and Terje Lømo 
(Bliss and Gardner-Medwin, 1973b, 1973a; Bliss and Lomo, 1973), and has 
been, since then, of more interest than LTD. Bliss and Lømo found in rabbit 
hippocampus that a few seconds of high frequency electrical stimulation can 
enhance synaptic transmission for days, or even weeks. 
The primary model of LTP investigation is the hippocampus, which is an 
anatomical structure strongly involved in learning. The best understood form of 
LTP is induced by the activation of the N-methyl-d-aspartate (NMDA) receptor 
complex. This receptor allows electrical events at the postsynaptic membrane to 
be transducted into chemical signals, which are thought to activate both pre- and 
post-synaptic mechanisms to generate a persistent increase in synaptic strength 
(Bliss and Collingridge, 1993). NMDA receptors (NMDAR) are referred to as a 
coincidence detector, because of the suggested ability to be able to respond to 
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the conjunction of activity in afferent fibres and adequate depolarization in target 
dendrites. 
 
Possible biochemical mechanisms 
Synaptic plasticity occurs when changes in gene expression and postsynaptic 
density complex take place at the same time. It needs the signalling of 
biochemical neurotransmitters to induce protein synthesis or spatial 
reorganisation. 
Long-term plasticity includes LTD and LTP, which have opposite effects 
regarding the strengthening or weakening of signaling between two neurons. 
 
Long-term depression 
LTD can be either activity-dependent or independent. What remains the same is 
the selective weakening of specific synaptic strength and, further, their efficacy in 
many areas of the brain. In simple words, LTD occurs when the postsynapse is 
not stimulated enough to induce LTP. Weak activation of NMDAR leads to a 
modest membrane depolarization, and to only a small rise in postsynaptic 
calcium (Ca2+) concentration. The lower concentration of Ca2+ leads to an 
activation of intracellular signaling molecules different from those in LTP, 
including serine phosphatases, which dephosphorylate critical synaptic 
substances, including the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
 Receptor (AMPAR) (Malenka and Bear, 2004). 
 
Long-term potentiation 
In contrast, LTP aims to optimize the signaling between two neurons. The three 
basic characteristics are: Cooperativity, associativity and input-specificity (Bliss 
and Collingridge, 1993). The molecular mechanism of LTP is most often induced 
by the activation of NMDAR at the post-synapse. AMPA channel is a receptor 
which modulates the action of the colocalized NMDAR (Siegel et al., 1995; 
Kharazia et al., 1996). The opening of NMDA channels is dependant on the 
degree of depolarization, and leads to a rise in Ca2+ concentration and an 
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activation of protein kinases (PK) in the post-synapse. A specific property of the 
NMDAR channel protein is the voltage-dependent blockage by magnesium 
(Mg2+). Only strong depolarization of the post-synaptic cell can displace Mg2+ 
from the channel, allowing calcium ions to enter. The increasing intracellular 
calcium concentration further leads to an increased excretion of intracellularly 
stored calcium (Ca2+) which activates downstream pathways, for example, the 
prominent change in AMPAR trafficking that results in an increased number of 
AMPAR in the post-synaptic plasma membrane with no effect on NMDAR. It is 
accompanied by observed enlargement of dendritic spines and associated 
postsynaptic densities (Yuste and Bonhoeffer, 2001; Malenka and Bear, 2004).  
 
There is evidence that NMDAR itself is not sufficient to induce LTP. Elements 
such as metabotropic glutamate receptor (mGluR) may be needed to induce long 
lasting cellular changes. MGluR-dependant LTP occurs in widespread areas of 
the brain, including the neocortex, hippocampus, striatum and nucleus 
accumbens. It is likely that the co-localization of mGluR and NMDAR leads to a 
release of Ca2+ from intracellular stores via activation of inositol triphosphat (IP3). 
LTP can involve the activation of mGluR1 or mGluR5, and can be either of 
AMPAR-mediated or NMDAR-mediated transmission (Anwyl, 2009). Studies 
have shown that selective antagonism of either mGluR1 or mGluR5 results in a 
significant impairment of both induction and maintenance of LTP in freely moving 
adult rats (Naie and Manahan-Vaughan, 2004; Manahan-Vaughan and 
Braunewell, 2005; Naie and Manahan-Vaughan, 2005). A study in transgenic 
mice, including animals with a lack of mGluR5, proposed that mGluR5 plays a 
regulatory role in NMDAR-dependent LTP (Lu et al., 1997). Another study 
showed that the animals displayed an abnormal hippocampal LTP expression, 
and an impaired ability in spatial learning and fear conditioning (Lu et al., 1997; 
Jia et al., 1998). The theory of a prominent influence of mGluR in LTP received 
further support by blockage studies which have shown a reduction in LTP 
duration (Reymann and Matthies, 1989; Izumi et al., 1991). 
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Another mechanism, also inducing LTP, depends on second messenger 
cascades. These processes regulate gene transcription and adapt the levels of 
core proteins at the synapse, such as Ca2+/calmodulin-dependent protein kinase 
II and protein kinase II. Initiation of this pathway leads to increased 
concentrations of these two kinases within the dendritic spine, and have been 
linked to growth in dendritic spine volume and LTP processes, such as the 
insertion of AMPAR in the synaptic membrane and a phosphorylation of ion 
channels; this receptor insertion, in turn, enhances the permeability of ions 
providing the mechanism for long-lasting memory storage.  
 
It remains unclear if LTP expression occurs in a single place only. There is a high 
probability that several loci exist; they interact with different and specific time 
courses: Pre-synaptic modification, post-synaptic modifications, extra synaptic 
changes and morphological modification (Chen et al., 2007; Citri and Malenka, 
2008).   
 
It is a matter of time until research will be able to answer this question. Up to 
now, electrophysiological recordings and biochemical assays have been used to 
investigate plastic changes. Highly advanced imaging techniques, in combination 
with fluorescent biosensors, offer us the required spatial and temporal resolution 
to study LTP in individual synapses. Last year, a report has been published, 
stating that the examination of cellular processes with single synapse resolution 
has undoubtedly enhanced our understanding of LTP (Padamsey and Emptage, 
2011). In contrast, technical development progressed, but the structure of 
investigation remained the same, the hippocampus (Padamsey and Emptage, 
2011).  
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1.5  The synaptic homeostasis hypothesis  
 
Five years ago, a promising hypothesis was postulated about sleep wake 
regulation on a cellular level. It provided a novel conceptual framework to 
address the still open question about the function of sleep. One of the best 
established facts in sleep regulation in mammals is that SWA increases in 
proportion to the duration of prior wakefulness, and progressively decreases 
during sleep (Borbély, 2001). The synaptic homeostasis hypothesis states that 
wakefulness is accompanied by synaptic potentiation in a large fraction of cortical 
circuits, and that sleep is necessary to renormalize the synaptic weight and 
consequently restore the synaptic balance (Fig. 8) (Tononi and Cirelli, 2003, , 
2006). In other words, according to the hypothesis, the change in brain plasticity 
by the synaptic potentiation, which occurs during wakefulness, is tied to the 
increase in SWA during the subsequent sleep episode, and are even positively 
related to each other. 
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Figure 8: The synaptic homeostasis hypothesis: a schematic diagram.  
Left side Synaptic potentiation and downscaling is suggested to be a cellular correlate of process 
S. Right side During wakefulness, when the organism is actively engaging in various waking 
tasks, strong synaptic activation is accompanied by a change in the neuromodulatory milieu (for 
example, high levels of noradrenaline (NA), which favors the storage of information by long-term 
potentiation. This process requires energy and space, and is thought to have a saturation level. 
The change from the wake- to the sleeping vigilance state causes a change in the 
neuromodulatory milieu, which triggers the occurrence of high amplitude slow oscillations, 
reflected in the EEG as SWA. Also the higher amount of synapses is suggested to lead to a 
higher synchronous cortical firing at the beginning of the night. During the progression of the night 
downscaling occurs; it is associated with energy saving, but also with space saving and an 
increased signal-to-noise ratio. At the end of the cycle, the slow oscillation disappears in 
correspondence to a lower number of synapses. The total amount of synaptic weight is back to 
baseline level but different to the spines. Thereby the synaptic balance is kept upright. White 
background: during wakefulness; dark background: during sleep (Tononi and Cirelli, 2006). 
 
By having a closer look at the brain physiology, it was observed that the firing of 
the noradrenergic system is high during wakefulness, and very low or even 
absent during sleep (Aston-Jones and Bloom, 1981). These molecules play an 
important role in the induction of LTP. Experimental lesion of the noradrenergic 
system led to an impairment in some forms of learning (Robbins and Everitt 
1995). Furthermore, plasticity-related genes, such as activity-regulated 
cytoskeleton-associated protein (Arc), Brain-derived neurotrophic factor (BDNF) 
or nerve growth factor inducible protein A (NGFI-A), have been suggested to be 
involved in LTP (Ying et al., 2002; Silva, 2003) and to be expressed preferentially 
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during wakefulness. In contrast, it could be shown that the expression of LTP-
related genes is severely reduced, or even abolished during sleep (Cirelli and 
Tononi, 2000). To sum up, spontaneous wakefulness is inevitably associated 
with some LTP-related molecular changes, while sleep is not (Tononi and Cirelli, 
2001). A recent study could even show brain plasticity-like features in Drosophila. 
The testing of three neuronal circuits in Drosophila (ventral lateral neurons, 
mushroom bodies, lobula plate vertical system) resulted in the finding that 
synapse size, or number, increases after a few hours of wakefulness, and 
decreases only if flies were allowed to sleep. The consequences of an enriched 
environment were both a larger synaptic growth and greater sleep need 
(Klintsova and Greenough, 1999; Bushey et al., 2011). Flies that were allowed to 
sleep after the enriched environment experience showed in all morphological 
parameters a decline to the levels observed in awake flies kept in single tubes 
(Bushey et al., 2011). Finally, overall levels of synaptic proteins in the fly’s brain 
increase after wake and decrease after sleep (Gilestro et al., 2009). Other 
techniques have been used to support the prediction of the increase in synaptic 
weight in the course of normal wakefulness and decline during sleep. Brain 
metabolism, as measured with water positron emission tomography (PET), 
showed that blood flow was 18% higher at the end of the waking period than 
after a night of sleep (Braun et al., 1997). The other approach was taken by 
recording miniature excitatory postsynaptic currents (mEPSCs) with whole-cell 
voltage clamp. Frontal cortex slices of mice and rats, which had been awake or 
asleep, were recorded. Independent of time of day, the outcome revealed an 
increase in the frequency and amplitude of mEPSCs after waking, and a 
decrease after sleep. Miniature EPSCs were also decreased after deprivation in 
the recovery sleep, supporting the suggestion that sleep favors synaptic 
homeostasis (Liu et al., 2010). 
 
These results suggest that a possible role of sleep in synaptic homeostasis can 
be shown by different techniques, and even in phylogenetically distant species; it 
may thus be of general importance. But there are also conflicting results, where 
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authors showed that the plastity of neurons is enhanced during sleep (Frank et 
al., 2001; Aton et al., 2009). 
 
 
1.6.  Glutamatergic mechanisms and signalling pathways in 
wakefulness and sleep, brain plasticity and disease 
 
Glutamate is considered the major excitatory neurotransmitter in the mammalian 
central nervous system (CNS). It can act through ionotropic (iGluR) and mGluR 
subtypes. The glutamatergic synapse attracted much attention in research, and 
knowledge has advanced enormously over the last ten years, primarily through 
application of cellular electrophysiological and molecular biological techniques to 
the mGluRs and transporters (GLTs) (Fig. 9). Today, eight subtypes of the 
mGluRs are identified and classified into three groups, based on their sequence 
identity, pharmacological properties and preferred signal transduction 
mechanism. Group I (mGluR1 and mGluR5) is coupled to phospholipase C 
(PLC), and up-regulates or down-regulates neuronal excitability. These receptors 
are localized predominantly on postsynaptic membranes (Niswender and Conn, 
2010). Furthermore, there is evidence that class I mGluRs, in particular mGluR5, 
are expressed on astrocytes and post-synaptic membranes of neurons and are 
critical in signal modulation (van den Pol et al., 1995; Cai et al., 2000; Fellin et 
al., 2004). Authors claim that glia are well positioned to modulate multiple 
aspects of synaptic plasticity (Barker and Ullian, 2010). Group II (mGluR2 and 
mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mGluR8) inhibit adenylat 
cyclase (AC) and, hence, reduce synaptic transmission. All mGluRs are 
polypeptides with a putative 7-trans-membrane spanning domain (Pin and Acher, 
2002). The activation of mGluRs has been implicated in a variety of CNS 
functions, such as learning, memory, anxiety, addiction, or pain perception 
(Swanson et al., 2005; Kauer and Malenka, 2007; Olive, 2009; Xu et al., 2009; 
Krystal et al., 2010; Jung et al., 2011). One mechanism underlying all these 
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functions is the synaptic plasticity, which is either beneficially changed or miss-
regulated.  
 
Figure 9: Schematic representation of the glutamatergic transmissions involving iGluRs and 
mGluRs in a synapse. The filled spheres indicate glutamate, and the question mark indicates that 
the function of mGluRs on astrocytes has not yet been fully elucidated.  
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; DAG: diadylglycerol; 
iGluR ionotropic glutamate receptor; IP3: inositol (1,4,5)-triphospate; MAPK: mitogen-activated 
protein kinase; mGluR: metabotropic glutamate receptor; NMDAR: N-methyl-D-aspartate receptor; 
PKC: protein kinase C; PLC: phospholipase C; PLD: phospholipase D (Gasparini et al., 2008a). 
 
Multiple proteins interact directly with the intracellular carboxy-terminal tail of 
each of the mGluR subtypes, and play important roles in their signaling cascade. 
Some of the best characterized molecules are Homer proteins. Distinct Homer 
gene and splice variants can differentially regulate localization of mGluR1 and 
mGluR5 in transfected cells and neurons. The protein contains domains 
interacting with the last several amino acids of mGluRs, which are critical for 
receptor activity or that mediate functional responses downstream of the 
receptors (Tu et al., 1998; Ehrengruber et al., 2004; Shiraishi-Yamaguchi and 
Furuichi, 2007; Niswender and Conn, 2010). A group of interest in sleep research 
is the so called Homer family of adaptor proteins, consisting in mammals of three 
members: Homer1, Homer2 and Homer3; all of which have several isoforms as a 
result of alternative splicing (Shiraishi-Yamaguchi and Furuichi, 2007). The long 
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Homer forms (including a coiled-coil domain at the carboxy-terminal) are 
constitutively expressed, bind to each other through their C-terminal domains, 
form a tetramer and bind to the target protein (Hayashi et al., 2006). These 
targets can be mGluR1α/5, IP3R, NMDAR and the actin cytoskeleton through 
their amino-terminal domains. Homers are highly concentrated at dendritic spines 
where they are involved in assembling various postsynaptic proteins. Homer1 
has, again, several splicing variants whereas Homer1a is of the greatest interest. 
It has a different protein structure, and a dynamic regulation in response to 
synaptic activity. Homer1a, which lacks the carboxy-terminal domain, is thought 
to compete with long Homer forms for binding to target proteins, for example 
IP3R, thus disrupting the clustering and therefore reducing glutamate-induced 
intracellular calcium release (Fagni et al., 2000; Shiraishi-Yamaguchi and 
Furuichi, 2007). In detail: The activation and opening of this IP3R channel protein 
results from the binding with IP3, assembled by a G-protein coupled receptor 
regulated PLC-β, which generates IP3 out of phosphatidylinositol 4,5-bisphospat. 
If the Homer1a concentration decreases in the cell, it leads to increased 
excitatory effects of mGluR5 activation, whereas an increased concentration and 
binding to the receptor lead to a reduction in intracellular calcium release. A 
study by Maret and colleagues found that Homer1a, as well as many other 
studied proteins, did not show a circadian expression pattern anymore when the 
animal was sleep deprived; this leads to the assumption that changes in gene 
expression are in fact sleep-wake dependent. With the hypothesis of Tononi and 
Cirelli in mind (Tononi and Cirelli, 2003, , 2006), these authors suggested that 
Homer1a, which is over-expressed after SD, could play a pivotal role in synaptic 
downscaling by buffering the intracellular calcium release (Maret et al., 2007). 
Under these circumstances, it is more difficult to excite a cell and initiate, and 
further elicit an action potential. One needs to keep in mind that not only 
neurotransmitter and receptors influence sleep, wakefulness and cellular 
properties, but also the genetic background. It is more and more appreciated that 
genetic variation is leading to inter-individual differences in vulnerability to sleep 
loss (Landolt, 2008a; Tafti, 2009). 
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A further area where the glutamatergic system plays a role is related to synaptic 
plasticity. Studies performed during the last 10 years revealed a prominent role of 
mGluRs in the processes of LTP and LTD. Anwyl reported that mGluRs are 
important in LTP, especially in the neocortex, hippocampus, striatum and nucleus 
accumbens; yet activation of other receptors may be involved in parallel (Anwyl, 
2009). The group around Tononi and Cirelli published several studies on this 
topic, too. According to the synaptic homeostasis hypothesis, they found on a 
molecular level that during wakefulness the phosphorylation of AMPARs, CamKII 
and GSK3β increased in contrast to sleep. During a period of sleep, a significant 
dephosphorylation of these receptors was observed compared to wakefulness 
(Vyazovskiy et al., 2008). 
 
A further method used to study the mGluR5 is the immunohistochemical staining. 
Results show that the distribution of mGluR5 mRNA is widely expressed with the 
highest density in the olfactory bulb, caudate, putamen, lateral septum, cortex, 
and hippocampus (Romano et al., 1995). In the cerebellum, only small amounts 
of mGluR5 mRNA were detected. In addition, a human PET study reported the 
anterior cingulate cortex (ACC), medial temporal lobe, amygdala, caudate, and 
putamen as regions with high and moderate mGluR5 density (Ametamey et al., 
2007). The same authors suggest that mGluR5 are possibly involved in diseases 
like anxiety, depression, schizophrenia, Parkinson’s, addiction, or pain 
(Ametamey et al., 2007). 
 
A recent study investigated the effect of major depression on mGluR5 density 
(Deschwanden et al., 2011). With the method of PET they found lower levels of 
mGluR5 binding in prefrontal cortex, cingulate cortex, insula, thalamus, and 
hippocampus. In addition, they observed negative correlations between the 
mGluR5 availability and depressive symptoms, as assessed with the Beck 
depression inventory, in all regions. The severity of symptoms was negatively 
correlated with mGluR5 binding in the hippocampus (bilaterally). Moreover, 
anxiety symptoms were negatively correlated with mGluR5 binding in thalamus, 
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orbito-frontal cortex (bilaterally), right frontal polar cortex and left middle cingulate 
cortex. 
 
A novel field of research emerged by the involvement of mGluR5 as a novel 
player in the treatment of fragile X syndrome (FXS). It is the most commonly 
inherited form of mental retardation and a leading known cause of autism 
(Krueger and Bear, 2010). The syndrome is caused by the repetition of a certain 
gene sequence on the X chromosome. The repetition results in a failure of the 
body to express the fragile mental retardation (FMR1) protein, which is required 
for normal neural development. Studies have examined the phenotypes of FXS 
in mice. Interbred with mGluR5 knockout animals have revealed that many of the 
phenotypes of FXS can be rescued when mGluR5 levels are reduced (Dolen et 
al., 2007). Also genetic reduction of mGluR5 signaling reduced FXS in mice 
(Bassell and Gross, 2008). Selective mGluR5 negative allosteric modulators  are 
used as treatment of FXS (Bear et al., 2004; Yan et al., 2005; Dolen et al., 2007). 
This protein is not only of interest for pharmaceutical companies, but also for 
researchers, since up to now it was believed that the progression of mental 
retardation diseases cannot be stopped. In 2011, a study conducted in 
drosophila suggested a link between sleep and FXS (Bushey et al., 2011). The 
study demonstrated that the fragile-X-mental retardation-1 gene (Fmr1) plays an 
important role in sleep-dependent synaptic renormalization. The authors cite an 
own study where they showed that Fmr1 protein levels increase in the adult fly 
brain during wakefulness relative to sleep, independent of time of day or night 
(Bushey et al., 2009). Thus, waking experience may be sufficient to affect Fmr1 
expression even after the end of development. 
 
The role of glutamatergic mechanisms in neurologoical diseases is and was the 
focus of many efforts to discover ligands as potential therapeutic targets to 
agonize or antagonize the glutamatergic transmission, and treat these disorders.  
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1.7  Sleep disorders 
 
Back in 1976, Bedrich Roth was one of the first researcher who influenced and 
formed the term of idiopathic hypersomnia (IH) (Roth, 1976). Patients with IH 
were subdivided into a symptomatic and a functional group. This grouping 
changed over the last 40 years several times and shows the difficulty to 
categorize this clinically heterogenous group. The main characteristic remained 
the same over the past years, namely, it is the disabling excessive daytime 
sleepiness (EDS) (Billiard, 2007). It needs to be mentioned that excessive 
sleepiness should be separated from fatigue and lack of energy associated with 
a variety of medical and psychiatric diseases. Today, little is known about the 
pathophysiology of IH; this is not surprising regarding the little research that was 
done with this patient group. A second reason is that no animal model of IH is 
available and, thus, experimental approaches are limited. A third reason is the 
low prevalence of this condition, which is assumed to be 0.002-0.02% of the 
general population (Billiard and Dauvilliers, 2001). Approximately 5% of patients 
in sleep clinics, who complain of daytime sleepiness, are diagnosed with IH 
(Bove et al., 1994; Bassetti and Gugger, 2000; Sforza et al., 2000). Despite the 
EDS, further symptoms have been observed and described in recent years. The 
International Classification of Sleep Disorders (ICSD-2) comprises the present 
classification of IH (AASM, 2005).  
Idiopathic hypersomnia is divided into two diagnostically different subgroups. The 
first group is referred to as IH with long sleep time. Despite no apparent nocturnal 
sleep disturbance, this group has three prominent features: Constant excessive 
daytime sleepiness with unwanted naps which are non-refreshing, prolonged 
nocturnal sleep, and laborious awakening in the morning and/or after naps 
(Vernet et al., 2010; Billiard, 2011). The clinical diagnosis comprises six 
characteristics: A complaint of EDS lasting more than 3 months; more than 10 
hours night sleep documented by actigraphy, sleep logs or interview, and sleep 
drunkenness in the morning; nocturnal polysomnography (PSG) revealing no 
other causes of daytime sleepiness; short sleep latency and more than 10 hours 
Chapter 1 
 28 
night sleep demonstrated by a polysomnogram; sleep latency in the multiple 
sleep latency test (MSLT) which is less then 8 minutes and fewer then 2 sleep 
onset REM (SOREM) sleep episodes; hypersomnia is not better explained by 
any other disorder. The second group is referred to as IH without long sleep time. 
The clinical diagnosis comprises the same six characteristics noted above with 
the difference in the second criteria of night sleep time between 6 and 10 hours 
(AASM, 2005; Billiard, 2007). 
The mentioned symptoms may vary in severity and occurrence across the 
patients. The course of the disease is initially progressive but often stable by the 
time of diagnosis, which is often several years after the onset. Idiopathic 
hypersomnia becomes apparent during adolescence or the early twenties, and 
appears to be a life-long disorder with no tendency to remit spontaneously. To 
counteract the EDS, stimulants, such as modafinil or antidepressants, are taken 
by IH, although not all patients respond to the medication. Antidepressants act 
mainly by blocking the re-uptake of monoamines into the synapses, leading to a 
higher concentration in the synaptic cleft and to an increased down-stream 
signaling (Zhou et al., 2007). 
 
Currently, only few polysomnographic studies of IH are available. One study 
found that the conventional sleep variables, and the cyclic alternation of NREMS 
and REMS episodes are undisrupted in patients with IH (Fig. 10A) (Bove et al., 
1994; Sforza et al., 2000). Further analysis of sleep spindles (SS) revealed that 
IH had an increased SS density at the beginning and the end of nocturnal sleep, 
and an increase in number of SS (Bove et al., 1994). Studying δ-activity revealed 
lower values in the patient group compared to healthy subjects (Fig. 10B) (Sforza 
et al., 2000); this led to the assumption of a disrupted homeostatic process. A 
study examining the secretion of melatonin and cortisol hypothesized a disturbed 
circadian rhythm by demonstration of a decreased melatonin concentration and a 
2-h delay phase shift. Cortisol concentrations were similar to healthy controls, 
though with a 4-h delayed shift (Nevsimalova et al., 2000). To elucidate a 
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possible dysregulation of homeostatic and/or circadian processes in IH patients, 
a sleep deprivation study would be beneficial. 
 
A                                                                   B 
  
Figure 10: Difference in slow-wave activity (SWA) between IH and control subjects. A Dynamics 
of the SWA over four consecutive sleep cycles in controls (straight lines) and IH patients (dotted 
line). In the patient groups, SWA was significantly lower during the first two NREM episodes but 
its temporal decay was preserved. B Individual SWA in NREMS for IH patients (triangles) and 
controls (circles). SWA is significantly lower in the IH patient group (Sforza et al., 2000).  
 
The opposite clinical entity of hypersomnia is insomnia. Most patients with 
insomnia have trouble falling asleep and experience frequent awakenings during 
sleep (Roth, 2007). Studies in this group found in the EEG power spectrum 
increased β-activity (Merica et al., 1998; Perlis et al., 2001), which is assumed to 
be an index of arousal, and decreased α-activity (Bonnet and Arand, 1994). The 
same authors, about 20 years later, wrote a review about hyperarousal and 
insomnia (Bonnet and Arand, 2010). They suggested that insomnia is associated 
with inappropriate physiological arousal; in particular, a state in which sleep and 
arousal systems are both simultaneously activated. They wrote that subjects with 
higher cardiovascular activity, which is an indirect measure of central nervous 
system arousal, had also higher sympathetic nervous system activation and 
therefore poorer sleep compared to controls (Bonnet and Arand, 2010). 
 
A related sleep disorder is narcolepsy (NC) which can occur with or without 
cataplexy. Men and women are equally affected, in contrast to IH, to which 
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woman are more prone (Lavault et al., 2011). The usual onset of NC lies 
between 15 and 30 years of age. The typical tetrade of symptoms is EDS, with 
continuous feeling of sleepiness or sleep attacks; the cataplexy with a sudden 
bilateral atonia of striated muscles with partial or complete weakness; the 
hypnagogic or hypnapompic hallucinations; and the sleep paralysis (Bassetti and 
Aldrich, 1997; Guilleminault and Brooks, 2001; AASM, 2005). Only 10% of 
patients experience the full tetrade. A frequent polysomnographic feature is the 
occurrence of sleep onset REMS periods (SOREMs) in the MSLT (Guilleminault 
et al., 1994; Aldrich et al., 1997).  
In many cases it is difficult to clinically differentiate patients with narcolepsy with 
cataplexy from patients affected by IH without long sleep time (Dauvilliers et al., 
2003), although recent studies could show polysomongraphic differences. 
Authors reported that patients with NC had shorter sleep onset and REMS 
latencies, lower sleep efficiency and sleep stage 1 percentage, shorter sleep 
latencies on the MSLT, and a higher amount of SOREMs than patients with IH 
(Lavault et al., 2011). Furthermore, NC showed significantly shorter sleep latency 
and REM latency than IH (Takei et al., 2012). A similarity between IH and NC is 
the response to modafinil, a wake promoting substance. Bastuji and Jouvet 
reported that modafinil decreased the number of daily naps in 15 out of 18 
patients with IH (83%); this is a percentage similar to the one seen in NC (Bastuji 
and Jouvet, 1988). With the intake of modafinil, the Epworth sleepiness score, a 
subjective estimation of the probability to fall asleep in a daily situation, was 
strongly reduced by 4.3 points in IH (Lavault et al., 2011). 
A prominent deficit and difference to IH is the loss, or reduced amount of 
hypocretin (Hrct) cells, also referred to as orexin, in the hypothalamus in NC 
(Billiard and Dauvilliers, 2001; Mignot et al., 2002). A study could show that the 
amount of these Hrct neurons and their transmission was reduced (Lin et al., 
1999; Mochizuki et al., 2004). Reduced Hrct levels were found in the 
cerebrospinal fluid (Nishino et al., 2000; Mignot et al., 2002), and, in addition, 
post mortem brain tissue showed a loss of Hrct cells (Thannickal et al., 2000). 
Even more interesting are the findings which show that Hrct plays an important 
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role in stabilizing the state of wakefulness and sleep (Adamantidis et al., 2007; 
Sakurai, 2007). A recent study even suggests that Hcrt promotes wakefulness 
whereas melanin concentrating hormone (MCH) induces REMS (Peyron et al., 
2011).  
 
Neurotransmitters are essential messengers between distinct brain areas. In the 
next section, some neurotransmitters and their sites of action will be discussed. 
 
 
1.8  Anatomical and physiological background of state 
transition between wakefulness and sleep 
 
Since von Economo’s report in 1916, that two distinct brain regions may be 
responsible for sleep and wakefulness problems, researchers have been 
interested in finding out what the underlying neuroanatomy and -transmitters are. 
Von Economo could identify a region between the brainstem and the forebrain 
that caused prolonged sleepiness, and a second site of lesion in the anterior 
hypothalamus that caused prolonged insomnia. One review, seven years ago, 
summarized the complexity of interactions in the brain between neurotransmitters 
and physiological mechanisms. It discusses the question in which anatomical 
structure arousals arise, and which neurotransmitters play a role in inducing a 
solid state of sleep or wakefulness (Saper et al., 2005).  
 
The complexity of the interacting neurotransmitters and their anatomical location 
are illustrated in more detail in the simplified schema in Figure 11.  
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A                                                                   B 
 
Figure 11: A A Schematic drawing showing some key components of the ascending arousal 
system. A major input to the relay and reticular nuclei of the thalamus (yellow pathway) originates 
from cholinergic (ACh) cell groups in the upper pons, the pedunculopontine (PPT), and 
laterodorsal tegmental nuclei (LDT). These inputs facilitate thalamocortical transmission. A 
second pathway (red) activates the cerebral cortex to facilitate the processing of inputs from the 
thalamus. This arises from neurons in the monoaminergic cell groups, including the 
tuberomammillary nucleus (TMN) containing histamine (His), the A10 cell group containing 
dopamine (DA), the dorsal and median raphe nuclei containing serotonin (5-HT), and the locus 
coeruleus (LC) containing noradrenaline (NA). This pathway also receives contributions from 
peptidergic neurons in the lateral hypothalamus (LHA) containing orexin (ORX) or melanin-
concentrating hormone (MCH), and from basal forebrain (BF) neurons that contain γ-aminobutyric 
acid (GABA) or ACh. 
B A schematic drawing showing the key projections of the ventrolateral preoptic neucleus (VLPO) 
to the main components of the ascending arousal system. It includes the monoaminergic cell 
groups (red), such as the tuberomammillary nucleus (TMN), the A10 cell group, the raphe cell 
groups, and the locus coeruleus (LC). It also innervates neurons in the lateral hypothalamus 
(LHA; green), including the perifornical (PeF) orexin (ORX) neurons, and interneurons in the 
cholinergic (ACh) cell groups (yellow), the pedunculopontine (PPT), and laterodorsal tegmental 
nuclei (LDT). 5-HT, serotonin; GABA, γ-aminobutyric acid; gal, galanin; NA, noradrenaline; His, 
histamine (Saper et al., 2005). 
 
The ascending arousal system (AAS) controls arousal and mental alertness 
(Steriade, 1996). The AAS was originally referred to as ascending reticular 
activating system 60 years ago (Moruzzi and Magoun, 1949) which originates in 
the brainstem and basal forebrain (BF), runs through the midbrain reticular 
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formation (RF) and innervates the thalamus and cortex (Moruzzi and Magoun, 
1949; Jones, 2005b; Saper et al., 2005). RF projection neurons are likely to use 
glutamate as a neurotransmitter (Jones, 1995),  and maintain cortical activation 
and behavioral arousals of wakefulness (Jones, 2005a). There are two pathways 
of the AAS: a dorsal and a ventral one (Fig. 11A). The two main regions in the 
dorsal pathway, which project with mainly cholinergic cells to the thalamus, are 
the pedunculopontine (PPT) and laterodorsal tegmental nuclei (LDT) (Hallanger 
et al., 1987). A study in animals showed evidence that the PPT has wake 
promoting function. The researchers injected glutamate into the PPT of rats and 
found an increased duration of wakefulness and REMS duration in a dose-
dependant manner (Datta et al., 2001). The activation of the thalamus by the 
PPT and LDT facilitates further thalamocortical transmission. The ventral 
pathway arises from several regions in the brainstem and caudal hypothalamus, 
bypasses the thalamus and projects to the BF and the cerebral cortex. These 
regions contain monoaminergic cell groups and include the locus coeruleus (LC, 
noradrenalin), the raphe nucleus (RN, serotonin), and the tuberomamillary 
nucleus (TMN, histamine). The ventral pathway is further activated by Hcrt cells 
originating in the lateral hypothalamus (Saper et al., 2005). Many of the Hcrt 
neurons contain glutamate (Torrealba et al., 2003). They send axons to the entire 
cerebral cortex, to the brainstem and BF, with particular input to TMN and the LC 
(Peyron et al., 1998). Hcrt neurons are suggested to play an important role in 
stabilizing wakefulness and sleep (Adamantidis et al., 2007; Sakurai, 2007). 
 
The ‘flip-flop switch’ model of sleep and wakefulness is presented in Figure 12. 
This model claims that wake and sleep are two distinct and consecutive vigilance 
states. Wakefulness is primarily initiated and stabilized by monoaminergic and 
cholinergic neurotransmission in the upper brain stem. The ventrolateral preoptic 
nucleus (VLPO) plays a key role in this model. Its action is either suppressed by 
the TMN, LC, and RN – with the effect of wakefulness – or, in contrast, the VLPO 
is highly active and suppresses these regions, resulting in the state of sleep. 
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Figure 12: A schematic diagram of the flip-flop switch model. During wakefulness (upper panel), 
the monoaminergic nuclei (red) inhibit the ventrolateral preoptic nucleus (VLPO; purple), thereby 
relieving the inhibition of the monoaminergic cells, and that of the orexin (ORX) neurons (green), 
and the cholinergic pedunculopontine (PPT) and laterodorsal tegmental nuclei (LDT; yellow). 
Because the VLPO neurons do not have orexin receptors, the orexin neurons serve primarily to 
reinforce the monoaminergic tone, rather than directly inhibit the VLPO on their own. During sleep 
(lower panel), the firing of the VLPO neurons inhibits the monoaminergic cell groups, thereby 
relieving their own inhibition. This also allows it to inhibit the orexin neurons, further preventing 
monoaminergic activation that might interrupt sleep. The direct mutual inhibition between the 
VLPO and the monoaminergic cell groups forms a classic flip-flop switch, which produces sharp 
transitions in state, but is relatively unstable. The addition of the orexin neurons stabilizes the 
switch. 5-HT, serotonin; ACh, cholinergic; eVLPO, extended ventrolateral preoptic nucleus; 
GABA, γ-aminobutyric acid; gal, galanin; LC, locus coeruleus; NA, noradrenaline; PeF, 
perifornical; REM, rapid eye movement; TMN, tuberomammillary nucleus (Saper et al., 2005). 
 
There are two components which play an important role in the state of 
wakefulness and sleep: AAS and VLPO. Recordings from VLPO neurons across 
the sleep-wake cycle, including sleep deprivation, showed that their firing rates 
increased with sleep EEG slow-waves (Szymusiak et al., 1998). These findings 
support the hypothesis of Figure 12 of a VLPO firing during sleep. 
 
These observations suggest that the reciprocal activities and interactions of 
different populations of wake- and sleep-promoting neurons are distinct, and that 
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each may contribute differently and at distinct points in time to the states of 
wakefulness or sleep. Hence, not one of the mentioned systems itself appears to 
be absolutely necessary for wakefulness or sleep, although each contributes in a 
unique way to its generation and maintenance (Jones, 2005b). 
 
The main message concerning IH and NC is that a well-defined state transition is 
missing; this is reflected by strong sleep inertia in the morning in IH, and sleep 
attacks during the day in NC. Possible mechanisms and models are discussed in 
the last chapter of this work.  
 
 
1.9  The aim of the thesis 
 
The general purpose of the current thesis is to investigate mechanisms 
regulating sleep and wakefulness. Physiological, biochemical, and behavioral 
measures were studied. 
To challenge the homeostatic process of sleep regulation, we performed sleep 
deprivation (SD) studies (see study design in appendix II & III). With this 
intervention, we first investigated a possible participation of mGluR5 receptor 
density in the homeostatic process in healthy individuals. Secondly, we used the 
same paradigm to investigate possible changes in the build-up of sleep need and 
alertness in patients with IH. 
 
In the first project (Chapter 2), mGluR5 density in the human brain was studied 
with the method of PET, aiming at enlarging the knowledge about receptor 
availability in response to prolonged wakefulness. Studies suggest that the brain 
undergoes plastic changes during wakefulness and sleep, namely, LTP and LTD 
respectively. Our hypothesis was that SD would lead to an increased mGluR5 
density in healthy male volunteers, since studies have suggested that sleep need 
is linked to neural plasticity. Studies have also shown that wakefulness is 
associated with synaptic potentiation that is another mGluR-mediated process. 
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We compared PET data of a control condition, where the subjects could sleep 
the night before the scan, with data collected after a night without sleep. 
 
The purpose of the second project (Chapter 3) was to study physiological sleep-
wake regulation in patients with IH. We aimed to obtain a deeper insight into the 
pathophysiology of this disease, which is characterized by excessive daytime 
sleepiness of unknown origin. Studies have shown that increasing sleep pressure 
during prolonged wakefulness is reflected by θ-activity in the waking EEG 
(wEEG), whereas during the subsequent recovery sleep the enhanced 
homeostatic process is reflected by predictable changes in δ-activity in the sleep 
EEG. We were interested to see if we could observe frequency-specific 
differences in EEG spectral power in the course of prolonged wakefulness. 
Furthermore, we studied and compared sleep parameters between IH patients 
and healthy controls in the recovery night after sleep deprivation. We addressed 
three specific questions: Do patients with IH have reduced tolerance to sleep 
pressure? Do they have an altered build-up of sleep need? Or, is there a 
disturbed interaction of the homeostatic and circadian processes?  
 
All data of this thesis were recorded in the sleep laboratory of the Institute of 
Pharmacology and Toxicology at the University of Zürich. I contributed to the 
data collection and the analyses of cognitive tasks, questionnaires, PET data, 
and EEG data. In preparation of the publications reporting the results described 
in Chapters 2 and 3, I drafted the first versions of parts of the manuscripts and 
revised them with the help of the co-authors. 
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Abstract 
Background: Sleep deprivation (“wake therapy”) provides rapid clinical relief in 
many patients with major depressive disorder (MDD). Changes in glutamatergic 
neurotransmission may contribute to the antidepressant response, yet the exact 
underlying mechanisms are unknown. Metabotropic glutamate receptors of 
subtype 5 (mGluR5) are importantly involved in modulating glutamatergic 
neurotransmission and neuronal plasticity. The density of these receptors is 
reduced in the brain of patients with MDD, particularly in brain structures involved 
in regulating wakefulness and sleep. We hypothesized that prolonged 
wakefulness would increase mGluR5 availability in human brain. 
Methods: mGluR5 binding was quantified with positron emission tomography 
(PET) in 22 young healthy men who completed 2 experimental blocks separated 
by one week. Two PET examinations were conducted in randomized, cross-over 
fashion with the highly selective radioligand, 11C-ABP688, once after 9 hours 
(sleep control) and once after 33 hours (sleep deprivation) of controlled 
wakefulness. 11C-ABP688 uptake was quantified in 13 volumes of interest with 
high mGluR5 expression and presumed involvement in sleep-wake regulation. 
Results: Sleep deprivation induced a global increase in mGluR5 binding when 
compared to sleep control (p< 0.006). In anterior cingulate cortex, insula, medial 
temporal lobe, parahippocampal gyrus, striatum, and amygdala, this increase 
correlated significantly with the sleep deprivation-induced increase in subjective 
sleepiness. 
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Conclusions: This molecular imaging study demonstrates that cerebral mGluR5 
availability is increased after a single night without sleep. Given that modulators 
of mGluR5 have antidepressant properties, further research is warranted to 
examine whether this mechanism is involved in the potent antidepressant effect 
of ‘wake therapy’. 
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Introduction 
The regulation of sleep and mood are tightly associated. Disrupted sleep 
is an important diagnostic criterion and risk factor for major depressive disorder 
(MDD) (Baglioni et al., 2010). Insomnia symptoms often precede the onset of 
depression by several months, are resistant to treatment, and increase the risk of 
relapse in remitted patients. Intriguingly, whereas sleep-wake disturbances are 
highly prevalent in MDD, sleep deprivation (“wake therapy”) provides rapid 
clinical relief in many patients (Bunney and Bunney, 2011). Changes in 
glutamatergic neurotransmission have been proposed to contribute to the 
antidepressant response, but the exact underlying mechanisms are unknown. 
Metabotropic glutamate receptors including metabotropic glutamate 
receptors of subtype 5 (mGluR5) play an important role in regulating 
glutamatergic neurotransmission (Sanacora et al., 2008). The density of mGluR5 
is reduced in various cortical and subcortical brain regions in patients with MDD 
when compared to healthy controls (Deschwanden et al., 2011). These receptors 
are present on post-synaptic neurons and glia cells and contribute to both long-
term depression (LTD) as well as long-term potentiation (LTP) (Ayala et al., 
2009; Izumi and Zorumski, 2012). Moreover, they are involved in sleep-wake 
related postsynaptic plasticity in rats (Tadavarty et al., 2011), and interact directly 
or indirectly with different molecular markers of sleep-wake regulation in animals 
and humans. These markers include Homer 1a (Franken et al., 2001; Maret et 
al., 2007), fragile X mental retardation protein (FMRP) (Bushey et al., 2009, , 
2011; Hays et al., 2011), brain-derived neurotrophic factor (BDNF) (Faraguna et 
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al., 2008; Bachmann et al., 2012) adenosine deaminase (Okada et al., 2003; 
Bodenmann et al., 2011) and the adenosine A2A receptor (ADORA2A) (Gallopin 
et al., 2005; Bodenmann et al., 2011). 
Prolonged wakefulness not only affects mood and other daytime functions 
including sleepiness, but also elevates sleep need in a recovery night when 
compared to a baseline night. The most reliable markers of sleep need are the 
amount of slow-wave sleep (SWS) and EEG slow-wave activity (SWA) in non-
rapid-eye-movement sleep (NREMS) (Achermann and Borbély, 2011). 
Functional brain imaging studies consistently suggest that ventro-medial 
prefrontal cortex, basal forebrain, insula, anterior cingulate cortex, striatum, 
parahippocampal gyrus, precuneus, and other regions, are importantly involved 
in the regulation of slow-waves and NREMS (Maquet et al., 1997; Dang-Vu et al., 
2008; Murphy et al., 2009). Interestingly, mGluR5 are preferentially expressed in 
most of these brain regions (Gasparini et al., 2008a, 2008b). In addition, they are 
important for shaping the EEG slow oscillation in NREMS (Blethyn et al., 2006) 
and synchronized “θ-mode” network activity in wakefulness (Cobb et al., 2000). 
Based on this convergent evidence for a possible involvement of mGluR5 in 
sleep-wake regulation, we aimed to quantify mGluR5 availability in rested and 
sleep-deprived state in humans. 
We used the recently developed, selective mGluR5 radioligand, 
11C-ABP688, to directly visualize mGluR5 availability in the living human brain 
(Ametamey et al., 2006; Ametamey et al., 2007). We quantified in healthy adults 
11C-ABP688 uptake in sleep control and sleep deprivation conditions in 13 brain 
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regions with high mGluR5 expression and presumed involvement in sleep-wake 
regulation. Given the recent observation that mGluR5 density is reduced in 
depressed patients (Deschwanden et al., 2011) and the suggested role of 
mGluR5 in sleep-wake related postsynaptic plasticity (Tadavarty et al., 2011), we 
predicted that prolonged wakefulness may increase mGluR5 availability in the 
brain. 
 
Materials and methods 
Study participants 
The study protocol and all experimental procedures were approved by the 
cantonal and federal authorities for research on human subjects, and carried out 
in accordance with the Declaration of Helsinki (1964). 
Twenty-two healthy young men completed the 2-week study after giving 
written informed consent. All volunteers were extensively screened for their 
medical history and psychological state. A pre-study screening night was 
performed in the sleep laboratory to exclude subjects with unknown sleep 
disturbances and low sleep efficiency (< 85 %). All participants were non-
smokers, right-handed, abstinent from any medication or illicit drugs, and did not 
cross time zones or do shift work during the last 3 months prior to the 
experiment. Validated questionnaires to assess life-style and demographic 
characteristics demonstrated the presence of a healthy study sample (Table 1). 
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Table 1. Demographic characteristics of study participants. 
Twenty-two male participants 
completed the study; one participant 
had to be excluded from PET 
analyses because of strong head 
movement. German versions and 
validated German translations of 
questionnaires were used to assess 
life style and personality traits. 
Caffeine consumption was estimated 
based on the following average 
caffeine contents per serving: 
Coffee: 100 mg; Ceylon or green tea: 
30 mg; Cola drink: 40 mg (2 dl); 
Energy drink: 80 mg (2 dl); 
Chocolate: 50 mg (100 g). Diurnal preference: Horne-Östberg Morningness-Eveningness 
Questionnaire (Horne and Östberg, 1976); daytime sleepiness: Epworth Sleepiness Scale (Bloch 
et al., 1999); trait anxiety: State-Trait Anxiety Inventory (Spielberger et al., 1970); depression 
score: Beck Depression Inventory (Beck et al., 1961); personality traits: Eysenck Personality 
Questionnaire (Francis et al., 2006) and Cloninger’s Tridimensional Personality Questionnaire 
(Weyers et al., 1995). 
 
Pre-study procedures and experimental protocol 
Three days before each study block, participants abstained from caffeine 
and alcohol, and adhered to a 16-hour wake/8-hour sleep schedule. Caffeine-, 
alcohol- and sleep logs, breath-alcohol measurements upon arrival in the 
laboratory, and wrist-actigraphy were used to verify adherence to these 
instructions. 
All subjects completed a sleep control and a sleep deprivation condition in 
randomized, cross-over fashion. Both experimental conditions consisted of 
 Mean ± SD 
Age (years) 23.4 ± 2.1 
Body-mass index (kg/m
2
) 22.1 ± 1.9 
Alcohol consumption (drinks/week) 3.5 ± 3.3 
Caffeine consumption (mg/day) 153.5 ± 160.9 
Diurnal preference 49.7 ± 8.4 
Daytime sleepiness 7.1 ± 3.3 
Trait anxiety 34.5 ± 7.0 
Depression score 3.2 ± 3.8 
Eysenck Personality Traits 
 Extraversion 
 Neuroticism 
 Lie scale 
 Psychoticism 
8.6 ± 2.8 
3.7 ± 2.8 
2.5 ± 1.9 
3.1 ± 1.4 
Cloninger Personality Traits 
 Novelty seeking 
 Harm avoidance 
 Reward dependence 
14.7 ± 5.6 
11.8 ± 4.7 
16.0 ± 5.2 
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polysomnographically-recorded adaptation, baseline, and recovery nights (time in 
bed: 23:30-07:30). In the sleep deprivation condition, the baseline night was 
followed by 40 hours continuous wakefulness during which the participants were 
under constant supervision of the research team. All subjects underwent 2 PET 
examinations with 11C-ABP688 to quantify mGluR5 availability in the brain 
(Division of Nuclear Medicine, University Hospital Zürich). These assessments 
occurred in random order, either ~ 9 or ~ 33 hours after awakening from the 
baseline night. The time-of-day of the PET examinations in sleep control (16:36 ± 
9 min) and sleep deprivation (16:34 ± 8 min) conditions did not differ (p > 0.4). 
 
Magnetic resonance (MR) and positron emission tomography (PET) image 
acquisition 
A T1-weighted, whole-brain, 3D-MR image (resolution: 1 x 1 x 1 mm) was 
obtained for each subject (Philips Achieva 3T whole-body MR unit equipped with 
T/R head coil), to exclude morphological abnormalities and as anatomical 
standard for the quantification of the PET images. 
Tracer synthesis and PET brain imaging with 11C-ABP688 using a 
bolus/infusion protocol were performed as previously described (Ametamey et 
al., 2006; Ametamey et al., 2007; Burger et al., 2010; Deschwanden et al., 2011). 
Catheters were placed into the antecubital veins of each participant’s arms, one 
for tracer injection and one for blood sampling. Venous blood was collected at 42 
and 58 min after the start of the bolus infusion. 
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All PET examinations were performed in 3D-mode on a DVCT PET/CT 
scanner (GE Healthcare) or a DSTx PET/CT scanner (GE Healthcare). A low-
dose computer tomography scan was performed before the PET examination for 
photon attenuation correction. The emission scans were initiated simultaneously 
with the start of the injection of 563.66 ± 20.35 MBq of radioligand using an 
infusion pump (PERFUSOR FM, BRAUN Medical); 47.6 % of the total activity 
(291 ± 7.1 MBq) was injected as a bolus over 2 min (Kbol = 53 min) and the rest 
continuously infused over 58 min (280.82 ± 6.84 MBq). The specific activity of 
11C-ABP688 at end of synthesis equaled 128.5 ± 10.4 GBq/μmol (range: 61 - 289 
GBq/μmol). Twenty frames were collected during the 60-min protocol (10 x 60 s 
and 10 x 300 s). The images were reconstructed using filtered back projection 
and displayed over 47 trans-axial slices. Using a 128 x 128 matrix the resulting 
voxel size was 2.3 x 2.3 x 3.2 mm. 
Subjects were instructed to not fall asleep during image acquisition and 
the EEG was simultaneously recorded according to established procedures 
(Bodenmann et al., 2009b; Bodenmann et al., 2011), to verify wakefulness during 
the PET examinations. As soon as sleep-like EEG activity was noted, they were 
alerted via an intercom. Direct contact with the subjects was avoided, to minimize 
movement artifacts. 
 
Image processing and quantification 
Image processing consisted of within-subject motion correction by 
realigning the average of frames 17-19 to the average of frames 2-10 (rigid 
Chapter 2 
 46 
matching), spatial normalization of averaged frames 17-19 to the Montreal 
Neurological Institute (MNI) template brain for definition of volumes of interest 
(VOI). Besides, the averaged frames 17-19 of the PET images were also co-
registered to the corresponding MR image to delineate the cerebellum (Burger et 
al., 2010). These steps were performed with the PMOD® software package, 
version 3.1 (PMOD Technologies, Zürich, Switzerland). Standard VOIs for the 
MNI template brain available in PMOD were used to measure radioactivity 
concentration in the normalized PET images (Tzourio-Mazoyer et al., 2002). 
Because PMOD provides no single VOI for cerebellum, this region was defined 
manually in each subject on the MR image and subsequently transferred to the 
corresponding PET images, to measure radioactivity concentration in this region. 
Tissue time activity curves (TAC) were generated for cerebellum, superior frontal 
cortex, putamen and thalamus in both hemispheres, to confirm that steady state 
of receptor binding was reached in frames 17-19 (45-55 min) of image 
acquisition. 
The average radioactivity concentration between 45-55 min was 
calculated in each VOI (Ct[VOI]). Because some venous blood metabolite analyses 
were unreliable due to technical difficulties, regional Vt values could not be 
obtained. Instead, quantification of the PET images was done by dividing the 
regional radioactivity concentration values with the corresponding value in the 
cerebellum (Ct[Cb]), to obtain Vnorm (Vnorm = Ct[VOI]/Ct[Cb]). This method was 
successfully used in previous studies to quantify mGluR5 availability in the brain 
(Burger et al., 2010; Deschwanden et al., 2011). Furthermore, a preclinical study 
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showed that 11C-ABP688 binding in the cerebellum is negligible and that this 
region can thus be used as a reference region (Elmenhorst et al., 2010). 
 
Behavioral and cognitive effects of sleep deprivation 
To document that sleep deprivation was successful, validated 
questionnaires were employed before each PET scan to assess subjective 
sleepiness (Karolinska Sleepiness Scale) (Akerstedt and Gillberg, 1990), state 
anxiety (State Trait Anxiety Inventory) (Spielberger et al., 1970), and affective 
state (Profile of Mood States) (McNair et al., 1981). Approximately 3 hours before 
each scan, the subjects also completed a cognitive test session consisting of the 
psychomotor vigilance task (PVT) (Dinges and Powell, 1985) and the Deese-
Roediger-McDermott (DRM) false memory paradigm (Deese, 1959; Roediger 
and McDermott, 1995). To approach a normal distribution, mean reaction time 
(RT) on the PVT was expressed as speed (1/RT) and the number of lapses 
(RT > 500 ms) was transformed by (√x+√[x+1]). 
 
Cortisol concentration in saliva 
Immediately prior to each PET examination, all study participants provided 
a saliva sample to determine the cortisol concentration as a measure of acute 
stress. Unstimulated saliva was collected by placing a salivette® (Sarstedt, 
Sevelen, Switzerland) under the tongue and keeping the head slightly inclined for 
1-2 min. The samples were stored at -20 °C until the biochemical analysis took 
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place. The saliva was centrifuged at 3000 rpm for 5 min before free cortisol was 
analyzed using an immunoassay with time-resolved fluorescence detection 
(Dressendorfer et al., 1992). 
 
Statistical analyses 
All statistical analyses were performed with SAS® 9.1 software (SAS 
Institute, Cary, NC). Mixed-effect analysis of variance (ANOVA) models included 
the factors ‘condition’ (sleep control, sleep deprivation), ‘region’ (13 VOIs), and 
‘hemisphere’ (left, right), as well as their interactions. Two-tailed, paired t-tests 
were conducted to localize significant differences. To limit the number of 
comparisons and to control for type-I errors, analyses of PET data were 
restricted to the pre-defined VOIs and the significance level was set at 
α < 0.0038 (Bonferroni correction: α = 0.05/13). To estimate the possible 
associations between the effects of sleep deprivation on mGluR5 availability and 
changes in behavioral and cognitive variables, regression analyses were 
performed and Spearman rank correlation coefficients were calculated. If not 
stated otherwise, only significant results are reported. 
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Results 
Regional uptake of 11C-ABP688 in human brain 
Axial, sagittal and coronal views of 11C-ABP688 binding in the brain of one 
single individual in sleep control and sleep deprivation conditions are presented 
in Fig. 1. Consistent with previous studies (Ametamey et al., 2007; DeLorenzo et 
al., 2012), regional uptake of 11C-ABP688 reflected the known distribution of 
mGluR5 with most pronounced binding in anterior cingulate, insula, medial 
temporal lobe, medial prefrontal cortex, striatum and amygdala. Lower 
radioligand binding was present in thalamus and substantially lower in 
cerebellum, which was used to calculate the normalized volumes of distribution 
(Vnorm). Visual inspection of TAC in distinct brain regions confirmed that a steady 
state of 11C-ABP688 uptake was reached 45 min after tracer injection in all 
participants and scans. 
Figure 1. Axial, sagittal and 
coronal views of 
11
C-
ABP688 binding in a 
representative individual. 
(A) Magnetic resonance 
image (MRI) template for 
anatomical reference. (B) 
Color-coded normalized 
volumes of distribution (Vnorm) 
of 
11
C-ABP688 after ~ 9 hours 
of wakefulness (sleep control 
condition). (C) Color-coded 
Vnorm of 
11
C-ABP688 after 
~ 33 hours of wakefulness 
(sleep deprivation condition). The crosshair was placed in the right caudate nucleus (coordinates 
according to the Montreal Neurological Institute brain atlas: -14, 14, 2). 
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Sleep deprivation increases mGluR5 availability in human brain 
Regional Vnorm values of 
11C-ABP688 in sleep control and sleep 
deprivation conditions are shown in Fig. 2. Prolonged wakefulness increased 
global Vnorm by 3.5 ± 1.1 % when compared to control (1.50 ± 0.02 vs. 1.55 ± 
0.02, p < 0.006). Mixed-model ANOVA with the factors ‘condition’, ‘region’ 
(volumes of interest [VOIs]) and ‘hemisphere’ revealed highly significant main 
effects of ‘condition’ (F1,20 = 184.5, p < 0.0001) and ‘region’ (F25,500 = 257.6, p < 
0.0001), yet no significant effect of ‘hemisphere’ (F1,20 = 0.1, p > 0.7). Thus, the 
data of left and right hemispheres were averaged. The increase in mGluR5 
binding was significant in anterior cingulate cortex (3.9 ± 1.3 %, p < 0.0006), 
insula (4.5 ± 1.3 %, p < 0.0001), medial temporal lobe (4.2 ± 1.0 %, p < 0.0005), 
parahippocampal gyrus (4.6 ± 1.1 %, p < 0.0002), striatum (4.8 ± 1.4 %, 
p < 0.0003), and amygdala (4.3 ± 1.2 %, p < 0.002). No VOI showed a reduction 
in 11C-ABP688 binding after sleep deprivation when compared to control. 
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Figure 2. Regional differences in 
mGluR5 density and effect of sleep 
deprivation. (A) Normalized volumes 
of distribution (Vnorm) of 
11
C-ABP688 
uptake in 13 regions of interest after 
~ 9 hours of wakefulness (sleep 
control). (B) Vnorm after ~ 33 hours of 
wakefulness (sleep deprivation). (C) 
Percent difference in Vnorm between 
sleep deprivation and sleep control 
conditions. The two measurements 
occurred in random order and were 
separated by one week. Data 
represent means + 1 SEM (n = 21). 
Asterisks indicate significant 
differences between sleep deprivation 
and sleep control conditions 
(‘condition’: p < 0.0038). Med. Sup. 
Front. Cortex = medial superior frontal 
cortex; PFC = prefrontal cortex. 
 
 
 
 
Increase in 11C-ABP688 binding correlates with increase in subjective sleepiness 
Sleep deprivation impaired subjective state and cognitive performance. 
Sleepiness, state anxiety, fatigue, lapses on the psychomotor vigilance task 
(PVT), and false alarms on the Deese-Roediger-McDermott false memory 
paradigm were increased after prolonged wakefulness when compared to control 
(Table 2). By contrast, vigor was reduced and PVT reaction times were 
prolonged. 
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Table 2. Behavioral and cognitive effects of sleep deprivation. 
 Sleep control Sleep deprivation p < 
Karolinska Sleepiness Scale 3.13 ± 0.28 5.04 ± 0.43 0.001 
State Anxiety Inventory 36.45 ± 2.07 40.73 ± 2.47 0.001 
Profile of Mood States (POMS) 
 Fatigue 
 Vigor 
 Depression/Anxiety 
 Irritability 
5.77 ± 1.49 
18.54 ± 1.35 
3.32 ± 1.42  
0.91 ± 0.53 
13.86 ± 2.22 
10.54 ± 1.38  
4.14 ± 2.08 
1.68 ± 0.72 
0.001 
0.001  
0.506 
0.284 
Psychomotor vigilance task 
 Mean reaction speed (s
-1
) 
 Lapses (transformed) 
3.79 ± 0.07 
2.29 ± 0.25 
3.50 ± 0.07 
4.71 ± 0.62 
0.001 
0.001 
Deese-Roediger-McDermott Paradigm 
 False alarms 
 False memory 
 Hit rate 
5.25 ± 0.99 
12.25 ± 0.55 
40.35 ± 1.51 
8.40 ± 0.86 
13.80 ± 0.68 
41.15 ± 1.80 
0.001 
0.067 
0.638 
Values represent means ± SEM (n = 22). P-values refer to 2-tailed, paired t-tests. Significant 
differences between sleep control and sleep deprivation conditions are highlighted in bold. 
 
Correlation analyses between the sleep deprivation-induced change in 
subjective sleepiness and the percent change in mGluR5 availability revealed 
consistent associations in all brain regions showing a significant increase in 11C-
ABP688 binding. In other words, those subjects who were most affected by sleep 
deprivation exhibited the largest increase in mGluR5 binding in anterior cingulate 
cortex, insula, medial temporal lobe, parahippocampal gyrus, striatum and 
amygdala  (Fig. 3). A similar association was also found for fatigue on the Profile 
of Mood States questionnaire and mGluR5 availability in medial temporal lobe 
(rp = 0.43, p = 0.053; rs = 0.45, p < 0.04; n = 21). The other behavioral and 
cognitive effects of sleep deprivation revealed no consistent correlation with the 
changes in mGluR5 binding in the significant VOIs.  
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Figure 3. Relationship between the individual subjects’ difference in subjective sleepiness 
and the difference in mGluR5 availability between sleep deprivation and sleep control 
conditions. Individual percent changes in normalized volumes of distribution (Vnorm) of 
11
C-
ABP688 in those brain regions that showed a significant increase after sleep deprivation are 
illustrated. A linear regression line was fitted through the 21 individual data points. 
KSS = Karolinska Sleepiness Scale; rp = Pearson’s product-moment correlation coefficient; 
rs = Spearman rank correlation coefficient. 
 
Cortisol concentration in saliva 
Prolonged wakefulness tended to slightly increase salivary cortisol 
concentration when compared to the sleep control condition (9.4 ± 0.6 vs. 7.0 ± 
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0.6 mmol/l, p < 0.08). The individual changes in salivary cortisol were not 
associated with individual changes in mGluR5 binding. 
 
Discussion 
This in vivo molecular imaging study in humans reveals the first evidence 
for increased cerebral mGluR5 availability after prolonged wakefulness. After a 
single night without sleep, binding of 11C-ABP688 was significantly increased on 
a global level, and in distinct brain regions that were previously shown to reflect 
physiological changes after sleep deprivation (for recent review, see (Dang-Vu et 
al., 2010)). These effects of short-term sleep loss are intriguing. The expression 
of G-protein coupled receptors (GPCR) on the cell surface is tightly regulated 
and provides a powerful mechanism of signal amplification (Nelson and Cox, 
2008). A recent study demonstrated that regional 11C-ABP688 binding may 
reflect mGluR5 protein expression (Deschwanden et al., 2011). Because 
mGluR5 density is reduced in major depression (Deschwanden et al., 2011), our 
findings suggest that changes in mGluR5 availability may be involved in the rapid 
antidepressant effect of sleep deprivation in MDD patients. 
The mGluR5 are mostly expressed on post-synaptic membranes of 
neurons and astrocytes in cortico-limbic areas of the brain, including medial-
prefrontal and orbito-frontal cortex, cingulate, striatum, amygdala and 
hippocampus (Gasparini et al., 2008a). They may be very well positioned to 
integrate and modulate the expression of established molecular markers of 
wakefulness and sleep. Indeed, mGluR5 interact either directly or indirectly with 
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Homer 1a, FMRP, BDNF, ADA, and ADORA2A. Convergent evidence obtained 
from studies in invertebrates, rodent models and humans strongly indicate that all 
these molecules play a causal role in sleep-wake regulation (Urade et al., 2003; 
Maret et al., 2007; Faraguna et al., 2008; Bushey et al., 2009; Bodenmann et al., 
2011; Bushey et al., 2011). 
For example, expression of the immediate early gene Homer 1a is 
increased after prolonged wakefulness (Maret et al., 2007). Homer 1a selectively 
uncouples mGluR5 from effector targets in the membrane of the post-synaptic 
density and attenuates the mGluR5-mediated rise in intra-cellular Ca2+ levels 
(Kammermeier and Worley, 2007). The interaction between Homer 1a and 
mGluR5 is necessary for mGluR5-dependent synaptic LTD (Ronesi and Huber, 
2008) and may promote synaptic changes during sleep (Maret et al., 2007). 
Not only Homer 1a but also FMRP interacts with mGluR5. A genetic defect 
in the X chromosome-linked human FMR1 (Fragile X mental retardation 1) gene 
encoding FMRP gives rise to increased mGluR5 signaling and Fragile X syndrome 
(FXS), the most common form of inherited mental retardation and a leading cause 
of autism. Brain slices of Fmr1 knock-out mice, an established model of FXS, show 
enhanced mGluR5-mediated synaptic LTD (Huber et al., 2002). In vitro as well as 
in vivo, these mice show prolonged spontaneous UP-states, which predominantly 
occur in SWS. This altered neocortical rhythmic activity is due to enhanced mGluR5 
signaling (Hays et al., 2011). Sleep-wake regulation was studied in Drosophila 
mutants carrying dFmr1 loss-of-function (amorphs) and gain-of-function 
(hypermorphs) mutations (Bushey et al., 2009). The dFmr1 amorphs were ‘long 
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sleepers’, whereas dFmr1 hypermorphs were ‘short sleepers’. A recent study 
further demonstrated that dFmr1 is important for sleep-dependent synaptic 
normalization (Bushey et al., 2011). 
Also interactions of mGluR5 with BDNF and adenosinergic 
neurotransmission may be important for sleep-wake regulation. Expression of 
BDNF in cerebral cortex is high during wakefulness, low during sleep, and 
increased after sleep deprivation (Cirelli and Tononi, 2000). Cortical injection of 
BDNF to awake animals promotes synaptic strength and enhances SWA in 
subsequent NREM sleep. This effect is reversible and opposite to the changes in 
local SWA after pharmacological inhibition of BDNF-tyrosine-kinase--receptor 
stimulation (Faraguna et al., 2008). Pharmacological activation of mGluR5 
induces BDNF expression in rat cortical neurons and glia cells (Legutko et al., 
2006; Viwatpinyo and Chongthammakun, 2009). It may, thus, be speculated that 
enhanced mGluR5-induced BDNF secretion after prolonged wakefulness 
contributes to the antidepressant response to sleep deprivation. Indeed, patients 
suffering from MDD typically exhibit reduced serum BDNF levels, which may 
normalize after antidepressant therapies (Nagahara and Tuszynski, 2011). 
The facilitatory action of BDNF on hippocampal LTP requires adenosine 
A2A receptor activation by endogenous adenosine (Fontinha et al., 2008). A 
primary role for adenosine and adenosine receptors in sleep regulation is well 
established in animals and humans (Basheer et al., 2004; Landolt, 2008b). In an 
approach similar to the present study, it was recently shown that sleep 
deprivation increases A1 receptor binding in human brain (Elmenhorst et al., 
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2007). Nevertheless, accumulating evidence indicates that also A2A receptors 
contribute to sleep-wake regulation (Gallopin et al., 2005; Bodenmann et al., 
2011). These receptors are co-localized with mGluR5, dopamine D2, and NMDA 
receptors, and functionally interact in vitro and in vivo (Ferre et al., 2002a, 2002b; 
Tebano et al., 2005; Ciruela et al., 2006b, 2006a; D'Ascenzo et al., 2007). 
Consistent with our results, a PET study in humans revealed that endogenous 
D2/3 receptor binding in the striatum was increased after sleep deprivation 
(Volkow et al., 2008). This increase was also associated with higher sleepiness 
and fatigue after sleep loss. 
Because plasma samples were not available for calculating regional Vt, 
the cerebellum was used to calculate Vnorm. mGluR5 receptor density in this 
region is unlikely to produce a specific binding signal with PET. Preclinical and 
clinical studies demonstrated that the cerebellum is suitable to quantify 11C-
ABP688 binding in the brain (Burger et al., 2010; Elmenhorst et al., 2010; 
Deschwanden et al., 2011). Another possible limitation of our study may be due 
to the fact that two different PET scanners were employed for examining the 
subjects. Because each volunteer was examined on the same scanner in sleep 
control and sleep deprivation conditions and a within-subject design was used, it 
is improbable that differences between PET scanners have biased the findings. 
In conclusion, the current observations indicate that mGluR5 are involved 
in the effects of sleep deprivation. This receptor has been implicated in various 
central nervous system pathologies, and pharmacological agents targeting 
mGluR5 currently provide promising future treatments for psychiatric and 
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neurological disorders including schizophrenia, anxiety, FXS, substance abuse, 
and drug withdrawal (Gasparini et al., 2008a, 2008b; Niswender and Conn, 
2010). Studies also suggest that mGluR5 agonists have antidepressant-like 
properties (Sanacora et al., 2008). Blockade of glutamatergic neurotransmission 
with the NMDA receptor antagonist ketamine and sleep deprivation therapy both 
rapidly reverse depression in a large subgroup of patients (Bunney and Bunney, 
2011). Given the reduced mGluR5 density in depressed patients (Deschwanden 
et al., 2011) and the enhanced mGluR5 availability after prolonged wakefulness, 
it is tempting to hypothesize that mGluR5 are involved in the rapid mood-
enhancing effects of sleep deprivation. Future research is needed to confirm this 
possible mechanism, and may lead to novel treatments of depression and other 
mental disorders which, according to the World Health Organization, will become 
the biggest health burden on society within the next 20 years. 
 
Acknowledgments 
We cordially thank all members of the Section of Chronobiology and Sleep 
Research, Institute of Pharmacology and Toxicology, University of Zürich, and 
the Division of Nuclear Medicine, University Hospital Zürich, who helped with 
data collection and analyses. 
 
 
 
Chapter 2 
 59 
Disclosure / Conflict of interest 
The work was supported by Swiss National Science Foundation grant # 
320030-135414, NCCR “Neural Plasticity and Repair”, and Novartis Foundation 
for Biomedical Research. ABP688 and its precursor were provided by Novartis 
Pharma AG. Drs. Sovago and Gomez-Mancilla are employees of Novartis 
Pharma AG (Basel), which is developing and testing drugs targeting the mGlu5 
receptor. Ms. Hefti, Mr. Holst, Dr. Bachmann, Dr. Buck, Dr. Ametamey, Mr. 
Scheidegger, Mr. Berthold, Dr. Seifritz and Dr. Landolt have no competing 
interests, financial or otherwise. 
Chapter 3 
 60 
Chapter 3 
 
Challenging sleep-wake regulation in idiopathic hypersomnia: 
Evidence for impaired arousal 
 
Katharina Hefti, MSc1; Ramin Khatami, MD2; Ursina Nadig, MSc1; Rositsa 
Poryazowa MD2; Birgit Högl, MD3; Claudio L. Bassetti MD2, and Hans-Peter 
Landolt, PhD1,4,5 
 
1 Institute of Pharmacology & Toxicology, University of Zürich, Zürich, 
Switzerland 
2 Department of Neurology, University Hospital Zürich, Zürich, Switzerland 
3 Department of Neurology, Medical University, Innsbruck, Austria 
4 Neuroscience Center Zürich (ZNZ), University of Zürich & ETH Zürich, Zürich, 
Switzerland 
5 Zürich Center of Integrative Human Physiology (ZIHP), University of Zürich, 
Zürich, Switzerland 
 
 
 
 
 
 
Manuscript in preparation 
Chapter 3 
 61 
Abstract  
Study Objectives: Patients with idiopathic hypersomnia (IH) suffer from 
excessive daytime sleepiness despite apparently undisturbed nocturnal sleep. 
The underlying pathophysiological mechanisms of IH are unknown. To 
investigate whether sleep homeostasis is altered in IH patients, we quantified 
sleep and waking EEG, as well as subjective sleepiness and neurobehavioral 
performance before, during, and after sleep deprivation. 
Design: Adaptation and baseline nights were followed by 40 hours of prolonged 
wakefulness and a subsequent recovery night. 
Setting: Sleep research laboratory. 
Participants: Ten drug-naïve patients diagnosed with IH (6 women, 4 men) and 
10 age- and sex-matched healthy controls completed the study. 
Intervention: Prolonged wakefulness of 40 hours. 
Measurements and Results: Visually scored sleep stages were similar in both 
groups. Prominently lower power in IH was present in α-, σ- and β-frequencies in 
non-rapid eye movement sleep (NREMS), and in the σ- and β-range in rapid-eye-
movement sleep (REMS). Spectral analysis of the waking EEG revealed similar 
results. Frequencies higher than 11.5 Hz showed lower power in patients than in 
controls. In addition, neurobehavioral performance during prolonged wakefulness 
was worse in patients, and they rated themselves as being sleepier than controls. 
By contrast, salivary melatonin and cortisol concentration showed a nearly 
congruent evolution over time spent awake in both groups (n=5 per group). 
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Conclusion: The data suggest that the homeostatic and circadian sleep 
regulatory processes are intact in IH. The disease is characterized by impaired 
brain arousal as evidenced by reduced high-frequency EEG activity, elevated 
sleepiness, and reduced performance in the absence of a sleep disturbance.   
Keywords: Idiopathic hypersomnia, sleep homeostasis, electroencephalogram, 
chronic fatigue, circadian. 
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Introduction 
IDIOPATHIC HYPERSOMNIA (IH) IS A DISABLING DISEASE, 
DIFFICULT TO DIAGNOSE, RARELY STUDIED, AND THEREFORE POORLY 
UNDERSTOOD. THE TERM iHS HAS GENERALLY BEEN USED WITH CAU- 
tion due to the incomplete knowledge regarding the neuro-anatomical structures, 
neuro-physiological, and biochemical factors involved in the control of sleep and 
wakefulness (Guilleminault and Brooks, 2001). The International Classification of 
Sleep Disorders (AASM, 2005) presents clear rules to diagnose IH. The main 
factors considered for diagnosis are the duration of persisting excessive 
sleepiness, the time in bed sleeping, polysomnogram (to exclude other causes of 
daytime sleepiness), and the Multiple Sleep Latency Test (MSLT). The excess of 
sleep, which is the most apparent feature in IH, is best expressed in unrestricted 
conditions, such as during the weekend, on holidays, or in the sleep laboratory 
with sleep permitted ad-libitum. The average additional sleep seen in iHS 
patients compared to healthy controls has been reported to be around three 
hours (Vernet et al., 2010). 
 A widely accepted concept in sleep research is the two-process-model. It 
postulates that sleep is influenced by the interaction of the homeostatic process, 
which increases with time spent awake, and the endogenously guided circadian 
process (Borbély, 1982). Electroencephalographic (EEG) δ-activity (0.5-4.5 Hz), 
also referred to as slow-wave activity (SWA), represents a marker of the 
homeostatic process and is present in non-rapid eye movement sleep (NREMS). 
δ-activity has a peak power in the beginning of the sleep period and decreases 
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with time spent asleep. The amount of δ-activity can fluctuate and is a reflection 
of sleep need, as extended wakefulness or sleep deprivation will increase the 
amount of δ-activity seen during sleep. Another important characteristic feature 
of NREMS is the occurrence of sleep spindles (12-15 Hz), which are prominent in 
sleep stage 2. In contrast to δ-activity, sleep spindles show an increase in power 
density as sleep progresses. Furthermore, after prolonged hours of wakefulness, 
σ-activity is suppressed compared to the increase seen in δ-activity (Dijk et al., 
1993). Rapid eye movement sleep (REMS) is the episode which follows a 
NREMS episode and ends a sleep cycle. With progression of the night, REMS 
episodes get longer. There might be two drives to enter REMS, namely, the 
homeostatic and the circadian drive. The homeostatic process, which is 
represented by δ-activity, rather suppresses REMS at the beginning of the night, 
and the circadian process leads to a favorable occurrence of REMS in the 
mornings (Aserinsky, 1969). After prolonged hours awake, the increased δ-
activity suppresses REMS density in recovery sleep suggesting an inverse 
relationship between REMS density and sleep depth (Feinberg et al., 1987). 
The interaction of the homeostatic process and the circadian process 
modulates not only sleep but also performance during the day (Borbély, 1982). 
The most disabling symptom IH patients suffer from is excessive daytime 
sleepiness (EDS). Therefore, the question arises whether the interaction of these 
two processes may be misaligned in IH. A frequently used protocol to study 
these processes is a period of prolonged hours awake. The homeostatic process 
can be estimated first by the difference in baseline and recovery night variables, 
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and second by an increase in specific EEG spectral parameters during the period 
awake. The circadian process can be assessed by repeated measurements of 
circadian biochemical markers such as melatonin (Cajochen et al., 2003), or 
cortisol in saliva (Van Cauter et al., 1996; Young et al., 2001). Measuring 
subjective sleepiness with questionnaires, or performance with computer-based 
cognitive tasks can also show the influence of both processes when monitored 
for more than 24 hours. The homeostatic process leads to an increase in 
sleepiness and a decrease in performance measures, whereas the circadian 
process leads to a partial improvement in performance the morning after one 
night of sleep deprivation.  
These sleep variables have been implicated in IH. Based on previous 
studies, different hypotheses arose why IH could lead to cognitive difficulties, 
particularly in relation to alertness. Analysis of sleep cycles in one study showed 
lower SWA in IH patients during the first NREMS episodes stemming from a 
decreased amount of stage 3 and 4 sleep (Sforza et al., 2000), which could 
reflect a dysfunction in the build-up and/or decay in the homeostatic process. A 
sleep deprivation to discriminate between these possibilities was not performed. 
The amount and density of sleep spindles in stage 2 sleep may also play a role. 
Spindles were compared in a study of narcoleptic patients (NC), IH and healthy 
controls, with results showing that hypersomnolent patients had higher sleep 
spindle density than controls. Since the thalamus is involved in the generation of 
spindles and plays a role in the gatekeeping functions in NREMS, authors 
suggested that thalamic dysfunction may be involved in the pathophysiology of 
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IH (Bove et al., 1994). A further indication of a changed sleep physiology in IH 
was found by studying REMS in more detail (Vankova et al., 2001). It was 
observed that the number of eye movements per minute in REMS during the 
whole night was increased, and the increase to consecutive REMS episodes was 
higher in IH of polysymptomatic forms when compared to healthy controls. The 
authors suggested that the oculomotor activity is not only homeostatically 
regulated, but that a factor accounting for the pathophysiology of primary 
hypersomnia may be the central arousal system (Vankova et al., 2001). A study 
with a biochemical setting monitored melatonin in saliva. Saliva was sampled in 
regular intervals for 24 hours and compared across IH, NC and controls. A clear 
reduction in melatonin concentration was observed between controls and IH and, 
in addition, to a two-hour delay (Nevsimalova et al., 2000), indicating a possible 
deregulation in biochemical signaling and a delayed sleep phase, or longer 
circadian period. This assumption was supported by a study showing that 
patients with IH are more frequently evening types, and that most of them suffer 
from disabling sleep drunkenness in the mornings (Vernet et al., 2010). Another 
reason for the problems in vigilance may be an imbalance in neurotransmitter 
systems, in particular a decrease in dopaminergic transmission (Montplaisir et 
al., 1982; Saper et al., 2005). 
The major aim of the study was to provide insighs into the 
pathophysiology of IH.  We focused on sleep homeostasis by measuring sleep 
and the sleep EEG in baseline and recovery nights after sleep deprivation. 
During 40 hours of prolonged wakefulness, we collected additional measures, 
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including waking EEG recordings, questionnaires, performance testing, 
melatonin, and cortisol levels in saliva, to monitor the build-up of the homeostatic 
process in patients with IH and matched healthy controls.  
 
Material & Methods 
Subjects 
The study procedures were approved by the cantonal ethic committee and 
carried out in accordance with the Declaration of Helsinki. All participants gave 
their written informed consent before participating in the study.  
Ten IH patients (6 women, 4 men) with a mean age 32.5 ± 4.2 years 
participated in the study. None of them took medication during the study period. 
Patients were diagnosed by an experienced sleep neurologist according to the 
International Classification of Sleep Disorder (AASM, 1990, , 2005), and informed 
about the sleep-study. Interested patients were contacted by the responsible 
person of the study and received detailed information about all procedures. 
Controls were recruited from the general public of Zürich and its agglomeration. 
The healthy control subjects were individually matched with respect to age and 
sex (mean age: 33.4 ± 4.13 years). Weight and height were similar between the 
groups. All subjects were moderate alcohol and caffeine consumers. All controls 
reported to be good sleepers, a statement which was confirmed with a screening 
night prior to the study. In addition, they had no significant past or present 
psychiatric or neurological disorders, and were free of any medication intake or 
illicit drug abuse. Demographics for both patients and healthy controls are 
presented in Table 1. 
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Table 1. Demographics of idiopathic hypersomnia patients and their age- and sex-matched 
healthy controls. 
 
 Idiopathic Hypersomnia Controls p= 
Gender ratio 6 women, 4 men 6 women, 4 men  
Age  32.5 ± 4.2 33.4 ± 4.1 0.215 
BMI 23.23 ± 0.9 23.67 ± 1.5 0.747 
Daytime sleepiness 13.3 ± 1.3 7.6 ± 1.1 0.016 
MSLT: SL  
             SOREM 
4.2 ± 0.4 
0.2 ± 0.1 
-- -- 
Trait anxiety 41.1 ± 2.7 35.2 ± 2.5 0.057 
Habitual sleep duration 
1
 8.4 ± 0.9 7.3 ± 0.2 0.403 
Habitual sleep duration 
2
 9.4 ± 0.6 8 ± 0.3 0.155 
Caffeine consumption 2.8 ± 0.9 2.4 ± 0.6 0.951 
Alcohol consumption 0.75 ± 0.2 2.7 ± 0.7 0.182 
Values represent means ± SEM (n=10). Statistics represent paired two-tailed t-test. 
BMI: Body mass index (kg/cm
2
); Daytime sleepiness was measured with the Epworth Sleepiness 
Scale; MSLT: Multiple sleep latency test; SL: mean sleep latency across four measurements 
during one day; SOREM: sleep onset REMS episode; TAI: Trait Anxiety Inventory; Habitual sleep 
duration
1
: reported habitual sleep length during working days; Habitual sleep duration
2
: reported 
habitual sleep length during days off; caffeine consumption: caffeinated beverages/day; alcohol 
consumption: drinks/week. Caffeine and alcohol data were not available for three patients and 
one control. 
 
Experimental Procedure 
Three days prior to the study week all participants had to adhere to a 
regular sleep-wake schedule (8/16) and were not allowed taking naps during the 
day. In order to ensure compliance, wrist actigraphy was continuously measured 
during this period. The subjects were also requested to avoid caffeine and 
alcohol three day prior to, and during the experimental period. 
Prior to the nights in the laboratory, saliva was taken for caffeine 
determination and breath alcohol was measured. The bedrooms were completely 
dark, temperature regulated and soundproof. The study design included an 
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adaptation night (AD) (23:30-07:30), a subsequent baseline night (BL) (23:30-
07:30), a consecutive period of 40 hours of wakefulness and a recovery night 
(REC) (23:30-09:30). During prolonged wakefulness, subjects were under 
constant supervision by the research team to ensure wakefulness, and were 
allowed to read, play games, study, watch TV, and take a walk outside the sleep 
laboratory. Starting 15 minutes after lights-on following the baseline night, and 
subsequently at 3hour intervals, waking EEGs were recorded and subjective 
state and cognitive performance were measured. In addition, a saliva sample 
was obtained at 2-hour intervals in five patients and five controls throughout 
sleep deprivation (Salivette®, Sarstedt, 9475 Sevelen). The samples were stored 
at -20°C for later melatonin and cortisol determination. 
One patient was unable to stay awake after 38 hours of prolonged 
wakefulness and initiated recovery night two hours earlier. For correct matching, 
the control subject went to bed after 38 hours as well. One IH patient was 
excluded from the EEG analyses due to a large deviation (> 2 SD) from the 
group mean. Because of a computer break-down lasting three hours, the EEG 
data of a recovery night in one IH patient were lost. 
 
Data collection 
Sleep and waking EEG 
Continuous polysomnographic recordings were performed during all 
nights. Electrodes for the EEG were placed on the subjects’ head according to 
the internationally used 10-20 system (Jasper, 1958). The surface electrodes 
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were placed at F3, F4, C3, C4, P3, P4, O1, and O2 and were referenced to A2. 
In addition, the electrooculogram (EOG), the electromyogram (EMG), and the 
electrocardiogram (ECG) were recorded by a polygraphic amplifier (PSA24; 
Braintronics, Almere, The Netherlands). The analog signals were conditioned by 
a high-pass filter (-3 dB at 0.16 Hz), a low-pass filter (-3 dB at 102 Hz and 
approximately -40 dB at 256 Hz), and a notch filter (50 Hz), digitized and 
transmitted via fiber-optic cables to a personal computer. Data were sampled 
with a frequency of 512 Hz, digitally filtered (EEG and EOG: low-pass FIR filter, -
3 dB at 49 Hz; EMG: band-pass FIR filter, -3 dB at 15.6 and 54 Hz), and stored 
on a hard disk with a resolution of 128 Hz. Sleep stage scoring was performed 
visually, based on the C3A2 derivation, and using 20 second epochs according 
to standard rules (Rechtschaffen and Kales, 1968). The first 8 hours of the 
baseline and recovery night recordings were analyzed. The night was also 
subdivided into NREMS (S2+S3+S4) and REMS episodes. The first four NREMS 
episodes were included in the analyses of the evolution of EEG power across 
consecutive frequency bins, and the following frequency bands: δ (0.75-4.5 Hz), 
α (8-12 Hz), σ (11.25-15 Hz) and β (15-20 Hz).  
EEG-raw data processing was performed with MATLAB (The MathWorks 
Inc, Natick, MA, USA) for sleep and waking EEG derived from the C3A2 
derivation. To approximate a normal distribution, absolute EEG power densities 
were log-transformed before statistical testing. 
EEG spectral power in sleep was computed for consecutive frequency 
bins (0.25 Hz resolution) in NREMS and REMS using the fast Fourier 
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transformation (FFT; Hanning window; average of five 4-s epochs; 0-20 Hz). 
Artifacts were identified by visual inspection, and a semiautomatic algorithm 
(moving average threshold) was used to separately exclude high- (20-40 Hz) and 
low- (0.75-4.5 Hz) frequency artifacts in each derivation.  
The waking EEG was measured according to standardized criteria. The 
subject was alone in a soundproof room, the light intensity was <150 lux and 
he/she had his/her chin resting on a headrest to avoid movement artifacts. Via 
intercom, the subjects were asked to sit relaxed and to close their eyes for 3 
minutes and open them for an additional 5 minutes recording. EEG, EOG, EMG 
and ECG signals were collected as described above. The waking EEG spectral 
power was computed by an FFT routine with some modifications, in contrast to 
the sleeping EEG (FFT, Hanning window, 50% overlapping 2 second epochs; 0.5 
Hz resolution; 0-30 Hz). Artifacts in the waking EEG were visually identified and 
excluded. Mean spectra with eyes open are reported. 
For time course analysis, the average of consecutive waking EEG 
sessions were calculated and expressed as a percentage of the average over all 
waking EEG recordings (Fig. 3). The last analysis comprised the determination of 
the α-peak during the period of prolonged hours awake. The absolute values 
were aligned to their individual α-peak ± SEM. Alpha-peak frequency was defined 
in each subject as the frequency bin with maximum power between 6 and 13 Hz. 
The α-peak frequency in patients was on average at 10.06 ± 0.51 Hz. Controls 
had their mean α-peak power at 10.39 ± 0.35 Hz. One subject in each group had 
no detectable α-peak and was excluded from this analysis. 
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Cognitive testing and biochemical markers 
 At 3-hour intervals subjective state was measured with the Karolinska 
sleepiness scale (KSS). In addition, neurobehavioral performance was measured 
using a 10minute psychomotor vigilance task (PVT, (Dinges and Powell, 1985)). 
Further information on the application of this task can be found in a previous 
publication (Bodenmann et al., 2009a). In addition, the current mood state was 
measured at 8 p.m. on the first day after 12 hours awake, and at 8 a.m. on the 
second day after 24 hours without sleep; this was accomplished with the state 
trait anxiety inventory (STAI, (Spielberger et al., 1970)).  
The direct saliva melatonin RIA kit was used to measure melatonin by a 
double-antibody radio immunoassay, based on the Kennaway G280 anti-
melatonin antibody, as in previous studies (Weber et al., 1997; Chellappa et al., 
2012). Cortisol concentration was determined by a luminescence immunoassay 
according to the previously described protocol (Ditzen et al., 2009). 
 
Statistical analyses 
For statistical analysis, the SAS 9.1 software was used (SAS Institute, 
Cary, NC). Two factor mixed-model analyses of variance (ANOVA) were 
employed, including main factors ‘group’ (patients, controls), ‘condition’ (BL, 
REC), ‘NREMS episode’ (1, 2, 3, 4), and ‘time’ (time intervals during SD). The 
significance level was set at α< 0.05 if not stated otherwise. To localize 
significant differences within a main factor, post-hoc paired two-tailed t-tests were 
performed. 
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Results 
Idiopathic hypersomnia patients show similar sleep architecture, whereas 
the spectral analysis reveals differences to healthy controls 
Visually scored sleep variables 
Sleep variables in baseline and recovery sleep are summarized in Table 
2. The two groups had similar sleep architecture in baseline sleep, and 
responded similarly to prolonged wakefulness in recovery sleep. The duration of 
stage 3 sleep was lower in IH in baseline and recovery nights. Sleep deprivation 
shortened sleep latency and increased sleep efficiency in the recovery night. 
Both groups showed a decrease in stage 1 sleep at the expense of increased 
stage 4 and SWS duration. As the only difference, the groups showed different 
responses to sleep deprivation in REMS latency. Controls showed a reduction in 
REMS latency in the recovery night when compared to the baseline night. This 
was not the case in patients with IH. 
 
All-night EEG power spectra  
Figures 1A and 1B present the whole night power spectra (0-20 Hz) in 
NREMS and REMS in baseline and recovery nights.  
In NREMS there was a ‘group’ effect in the ranges 0-0.25 Hz, 3.5-10.25 
Hz, 13.25-15 Hz and 17-20 Hz, and an effect of ‘condition’ in the range 0.5-9 Hz. 
Illustrating the patients’ values relative to controls and performing paired two-
tailed t-tests revealed lower power in IH in the 6.5-9.5 Hz and 15.75-20 Hz 
ranges in baseline sleep and in the 7.5-9.5 Hz band in recovery sleep (Fig. 1C). 
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Analyzing frequency bands in NREMS revealed a clear response to prolonged 
hours awake by an increase in δ-power in recovery night, as compared to 
baseline night in both groups (Tab. 3). 
An analysis of REMS power spectra revealed a prominent ‘group’ effect in 
the range 0-20 Hz, except the second bin, and a ‘condition’ effect in the range 1-
2 Hz and 2.5-4.25 Hz. Plotting patient values relative to controls, as described 
previously, revealed lower power in IH in baseline (1.75-2 Hz, 3.25-4.25 Hz, 5-
7.5 Hz and 11.25-20 Hz) and recovery night (1.5, 6, 10.25, 11.25, 15 Hz and 
15.5-16 Hz and 16.75-20 Hz) compared to controls (Fig.1D). Sigmapower was 
lower in IH patients in both nights. Patients with IH showed decreased β-power in 
baseline and recovery nights. Detailed output of frequency band analysis of 
NREMS and REMS is given in Table 3. 
 
Evolution of EEG power across NREMS episodes 
The evolution of EEG activity over the first four NREMS episodes was 
analyzed separately for baseline and recovery nights. Baseline sleep analysis 
revealed an effect of ‘group’ between 2.75-12 Hz and 13-20 Hz, and an effect of 
‘NREMS episode’ in 0-10.75 Hz frequencies (Fig. 2A and 2B). The same 
analysis, performed for recovery night, revealed a ‘group’ effect in 0-11.25 Hz, 
13-17.5 Hz, 18.25-19 Hz and 19.75-20 Hz frequencies. A prominent effect of 
‘NREM sleep episode’ was present between 0-11 Hz (Fig. 2C and 2D). 
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Figure 1. Sleep EEG data represent the first 8 hours after lights-off and derive from the 
C3A2 derivation. A & B: EEG power spectra in NREMS (left) and REMS (right) in baseline (BL) 
and recovery nights (REC) in 10 IH patients (black lines) and 10 controls (grey lines). Mixed 
model ANOVA, with factor ‘group’ and ‘condition’, revealed for NREMS a significant ‘group’ effect 
in the ranges 0-0.25 Hz, 3.5-10.25 Hz, 13.25-15 Hz and 17-20 Hz (F1, 27 > 4.3, p < 0.05), and a 
‘condition’ effect in the range 0.5-9 Hz (F1, 27 > 5.48, p < 0.05). Mixed model ANOVA with factor 
‘group’ and ‘condition’ in REMS revealed a highly significant ‘group’ effect from 0-20 Hz except 
the second bin (F1, 24 > 4.79, p < 0.05), a ‘condition’ effect in the range 1-2 Hz and 2.5-4.25 Hz (F1, 
24 > 4.3, p < 0.05). Triangles represent a significant ‘group’ effect, and diamonds represent a 
significant effect of ‘condition’. No bin revealed a significant ‘group*condition’ interaction. 
C & D: EEG power values of IH are expressed as a percentage to the control values for NREMS 
and REMS in baseline- and recovery night. A paired two-tailed t-test is performed to compare the 
two groups. IH have lower power in NREMS in baseline night in the ranges 6.5-9.5 Hz and 15.75-
20 Hz and in recovery night in the range 7.5-9.5 Hz. IH have lower power in REMS in baseline 
night in the ranges 1.75-2 Hz, 3.25-4.25 Hz, 5-7.5 Hz and 11.25-20 Hz, and in recovery night in 
the frequency bins at 1.5, 6, 10.25, 11.25, 15 Hz and the ranges 15.5-16 Hz and 16.75-20 Hz 
except the second last bin. Grey triangles represent lower power in baseline night iHS compared 
to healthy controls (p< 0.05) and in black diamonds in recovery night respectively. 
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Figure 2.  A - D: Analysis of the first four NREMS episodes. Cycles two, three and four are 
expressed as a percentage of the corresponding mean value of the first NREMS episode. Two-
way ANOVA was performed for BL and REC separately with main factors ‘group’ and ‘NREMS 
episode’. Analysis of BL night data revealed a significant ‘group’ effect in the ranges 2.75-12 Hz 
and 13-20 Hz (F1, 56 > 4.63, p< 0.05) and further a ‘NREMS episode’ effect in the ranges 0-10.75 
Hz (F3, 56 > 2.82, p< 0.05). Analysis with REC night data revealed similar results. A significant 
‘group’ effect in the ranges 0-11.25 Hz, 13-17.5 Hz, 18.25-19 Hz and 19.75-20 (F1,54 > 4.08, p< 
0.05), and further a ‘NREMS episode’ effect in the ranges 0-11 Hz (F3, 54 > 3.35, p< 0.05). 
Triangles represent significant main effect of ‘group’ in BL and REC sleep, diamonds represent 
significant main effect of ‘NREMS episode’ in baseline and recovery night respectively. 
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Idiopathic hypersomnia patients have lower β-power during prolonged 
wakefulness 
Power spectra during wakefulness 
The power spectra (0-30 Hz), averaged over all 14 measurements during 
prolonged wakefulness, are visualized in Figure 3A. Paired two-tailed t-tests 
revealed in patients lower power in a broad range (11.5-30 Hz except bin at 15 
Hz, p< 0.05). 
 Alignment to the α-peak revealed no difference in their position. Patients 
had a similar mean α-peak at 10.06 ± 0.51 Hz to controls α-peak at 10.39 ± 0.35 
Hz (p= 0.66, paired two-tailed t-test).  
 
Evolution of spectral power over 40 hours of wakefulness 
To examine whether the evolution of EEG frequencies during prolonged 
wakefulness differs between the groups, the waking EEG was studied in more 
detail. Figures 3B and 3C visualize the effect of sleep loss on the waking EEG. 
Means of four consecutive waking EEG recordings were expressed as a 
percentage of the averaged EEG power over all 14 recordings. A large frequency 
range revealed statistical ‘group’ effect (2 Hz, 5.5-30 Hz). The factor ‘time’ was 
significant in δ-/θ-frequencies (0.5, 3.5-5.5 Hz) but no significant ‘group’ x ‘time’ 
interaction was present. 
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Figure 3. Waking EEGs were 
collected in 3-hour intervals 
during the 40 hours without sleep. 
Data with eyes open from the 
C3A2 derivation are presented.  
A Mean absolute power density ± 
SEM is presented in IH and controls; 
all 14 measurements averaged. 
Paired two-tailed t-test revealed 
significantly lower power in IH 
between 11.5-30 Hz except for 15 Hz 
bin. Triangles represent p< 0.05. B & 
C Evolution of EEG power density in 
IH patients and healthy controls 
during prolonged hours awake. Mean 
over 4 consecutive measures were 
plotted relative to mean value over all 
wEEG. Two-way ANOVA with factor 
‘group’ and ‘time’ and their 
interaction revealed significant main 
effect of ‘group’ in 2 Hz, 5.5-30 Hz 
(F1.59 > 4.8, p< 0.05), and an effect of 
‘time’ in the first bin and in 3.5-5.5 Hz 
frequency bins (F3, 59 > 3.06, p< 
0.05). Triangles in B represent 
‘group’ effect and diamonds 
represent in C ‘time’ effect.  
Reference line (100%) represent 
mean over all wEEG; solid line: 
mean over wEEG within 12 hours 
awake; dashed line: mean over 
wEEG during the time window 12-24 hours awake; dotted line: mean over wEEG during the time 
window 24-23 hours awake. 
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Idiopathic hypersomnia affects daytime functions 
Subjective state 
The evolution of subjective sleepiness was quantified with the Karolinska 
Sleepiness Scale (KSS). The values are represented in Figure 4A and show 
significantly higher sleepiness in patients than in controls throughout prolonged 
wakefulness (‘Group’ F1, 224 = 66.03, p< 0.0001).  
The state anxiety inventory revealed a significant effect of ‘time’ (‘time’   
F1, 27 = 12.08, p< 0.002). Patients had a score of 39.7 ± 2.5 at 8 p.m. the first 
evening, and 44.1 ± 3.3 at 8 a.m. after one night without sleep. Controls showed 
a score of 33.0 ± 3.1 at day one and of 44.1 ± 3.8 on day two. Paired two-tailed t-
test revealed a significantly higher anxiety score on the first evening in patients 
with IH compared to healthy controls (p= 0.04).  
 
Psychomotor vigilance task (PVT) 
Performance on the PVT shows detrimental effects in healthy volunteers 
after prolonged wakefulness (Durmer and Dinges, 2005). Here, three PVT 
variables were analyzed (Fig. 4B-D). The fastest 10th percentile of reaction times 
(RTs) showed that patients were able to perform RTs equally fast as controls, 
even after prolonged hours awake (‘Group’ F1, 29.8 = 1.56, p> 0.22). By contrast, 
the slowest 10th percentile of RTs showed slower speed in patients throughout 
the whole period (‘Group’ F1, 30.8 = 16.7, p< 0.001). In addition, the number of 
lapses (RT> 500 ms) was higher in patients than in controls (‘Group’ F1, 38.4 = 9.0, 
p< 0.005).  
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Figure 4. Effect of 40 hours prolonged wakefulness on subjective and objective measures. 
Data were collected at 3-hour intervals during sleep deprivation. All four measures show a 
circadian modulation and increased homeostatic sleep pressure on the second half of the period 
without sleep. A Time course of sleepiness quantified with the Karolinska Sleepiness Scale 
(KSS). Throughout the whole period IH felt sleepier than controls. ‘Group’ F1, 86.1 = 73.14, p< 
0.001; ‘time’ F12, 126 = 21.48, p< 0.001; ‘group*time’ F12, 149 = 0.93, p= 0.5148. B Time course of 
transformed lapses ( 1 xx ; RT > 500 ms) on the PVT. Similar to the slowest RTs, IH had 
more lapses than controls during prolonged hours awake. ‘Group’ F1, 38.4 = 9.0, p< 0.001; ‘time’ 
F12, 140 = 8.18, p< 0.001; ‘group*time’ F12, 135= 0.57, p= 0.8638. C Time course of the slowest 10
th
 
percentile of RTs on the PVT. During the whole period iHS had slower RTs than controls. ‘Group’ 
F1, 30.8 = 16.70, p< 0.001; ‘time’ F12, 149 = 7.2, p< 0.001; ‘group*time’ F12, 138 = 0.66, p=0.7854. D 
Time course of the fastest 10
th
 percentile of reaction times (RT) on the psychomotor vigilance 
task (PVT, task duration: 10 minutes). The graph shows a nearly congruent evolution of the 
fastest RT between the groups. Statistics show no significant difference between iHS  and 
controls ‘group’ F1, 29.8 = 1.56, p> 0.22; ‘time’ F12, 147 = 6.24, p< 0.001; ‘group*time’ F12, 136 = 0.1.89, 
p= 0.0404. Values represent means ± SEM in 10 IH patients (black symbols) and 10 controls 
(grey symbols).  
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Idiopathic hypersomnia does not influence endocrinological markers of 
circadian clock output 
Melatonin 
The evolution of salivary melatonin concentration was nearly congruent across 
the groups (Fig. 5A). Averaged melatonin concentrations during the night (8 p.m. 
to 8 a.m.) were 2.65 ± 1.44 pg/ml in patients with IH and 3.08 ± 1.58 pg/ml in 
controls (p< 0.37). All absolute values were in the normal physiological range 
(Burgess and Fogg, 2008). 
 
Cortisol 
The evolution in salivary cortisol concentration revealed no difference between 
the two groups over 40 hours of prolonged wakefulness (Fig. 5B). The maximal 
concentration was seen in both groups within a time window of 2 hours (7 to 9 
a.m.). The absolute concentrations (mean over 24h: iHS: 8.6 ± 1.69 nmol/ml; 
CON: 9.02 ± 2.47 nmol/ml) lay in both groups in the standard range of healthy 
individuals and did not differ across the groups (p< 0.63) (Aardal and Holm, 
1995).  
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Figure 5. Salivary melatonin and cortisol profiles in saliva during prolonged wakefulness. 
Saliva was sampled in 2-hour intervals during the sleep deprivation period. The evolutions of both 
biochemical variables show normal circadian modulation in diseased and healthy subjects.  
Saliva was available in 5 matched subjects of each group. Values represent z-scores per group ± 
SEM; Black symbols represent idiopathic hypersomnia patients (IH), grey symbols represent 
control subject (CON). 
Mixed model ANOVA of melatonin data, with factor ‘group’ and ‘time’, revealed a highly significant 
effect of ‘time’ but none for ‘group’ and their interaction. ‘Group’ F1,156 = 0.21, p= 0.6505; ‘time’ F19, 
156 = 4.99, p< 0.0001; ‘group*time’ F19, 156 = 0.24, p= 0.9997. 
The same results arouse for cortisol analysis. ‘Group’ F1,156 = 0.15, p= 0.7017; ‘time’ F19, 156 = 
9.78, p< 0.0001; ‘group*time’ F19, 156 = 0.56, p=0.9263.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 83 
Table 2. Visually scored sleep variables for baseline and recovery sleep in idiopathic hypersomnia patients and controls. 
 
Variable Idiopathic Hypersomnia 
Baseline            Recovery 
Controls 
Baseline            Recovery 
‘Group’ 
F1,26 (p) 
‘Condition’ 
F1,26 (p) 
‘Group’ x 
‘Condition’ 
F1,26 (p) 
WASO 4.6 ± 1.4 6.6  ± 3.5 11.1 ± 4.8 6.4 ± 3.1 2.19 (0.15) 0.47 (0.50) 1.84 (0.19) 
Stage 1 30.0 ± 7.9 17.2 ± 4.4 † 23.0 ± 4.1 12.7 ± 2.7 † 1.78 (0.19) 9.62 (0.0046) 0.21 (0.65) 
Stage 2 207.3 ± 9.5 194.8 ± 10.2 205.6 ± 9.0 195.3 ± 12.5 0.01 (0.94) 2.43 (0.13) 0.08 (0.77) 
Stage 3 30.7 ± 3.2 32.7 ± 3.8 39.6 ± 5.4 41.7 ± 4.9 6.11 (0.0203) 0.56 (0.46) 0.03 (0.89) 
Stage 4 64.5 ± 11.7 101.3 ± 13.1 † 58.6 ± 10.1 103.2 ± 14.7 † 0.27 (0.61) 39.26 (0.0001) 0.13 (0.72) 
SWS 95.2 ± 13.5 134.0 ± 12.1 †  98.2 ± 12.5 144.9 ± 17.3 † 0.43 (0.52) 37.96 (0.0001) 0.06 (0.81) 
REM 111.6 ± 4.6 107.0 ± 5.5 113.6 ± 7.0 104.7 ± 4.9 0.00 (0.97) 1.44 (0.24) 0.15 (0.70) 
MT 14.1 ± 2.0 11.0 ± 0.9 14.9 ± 1.7 10.7 ± 1.6 †  0.03 (0.86) 6.33 (0.0182) 0.13 (0.72) 
TST 444.1 ± 6.5 453.0 ± 4.5 440.4 ± 5.7 457.6 ± 2.5 † 0.00 (0.95) 14.42 (0.0008) 1.29 (0.27) 
SL 17.1 ± 5.2 9.4 ± 2.7 ‡ 12.7 ± 4.6 5.3 ± 1.5 1.73 (0.2) 5.18 (0.0312) 0.00 (0.98) 
RL 55.4 ± 7.1 66.5 ± 10.4 63.4 ± 2.9 55.6 ± 2.2 † 0.72 (0.4) 0.77 (0.39) 4.70 (0.0393) 
SEFF 92.5 ± 1.4 94.4 ± 1.4 91.8 ± 1.2 95.3 ± 0.5 † 0.01 (0.94) 14.21 (0.0008) 1.27 (0.27) 
 
Values represent means ± SEM in minutes (except sleep efficiency in %) of nine idiopathic hypersomnia patients and controls. The first 8 hours (= 
480 minutes) after lights-off were analyzed. † p< 0.03 (paired, two-tailed t-test within group); ‡ p< 0.05 (paired, two-tailed t-test between group). 
Patients with IH show similar amount of sleep variables as their healthy controls. The interaction of REM sleep arose because one subject started 
with sleep onset REM. Exclusion of this subject revealed the following statistical values: ‘group’ 2.00 (0.17); ‘condition’ 0.16 (0.79); ‘group’ x 
‘condition’ 3.13 (0.09). 
WASO: Wake After Sleep Onset; SWS: Slow Wave Sleep (Stage3 and 4) REM: Rapid Eye Movement; MT: Movement Time; TST: Total Sleep 
Time; SL: Sleep Latency (first occurrence of stage 2); RL: REM Latency; SEFF: Sleep Efficiency (percentage of TST per 480 minutes). Due to 
computer breakdown, the data of one patient’s recovery night are missing. 
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Table 3. Power in NREM and REM sleep EEG in distinct frequency bands. 
 
 Idiopathic Hypersomnia 
Baseline            Recovery 
Controls 
Baseline            Recovery 
‘Group’ 
F 1, 27 (P) 
‘Condition’ 
F 1, 27 (P) 
‘Group’ x 
‘Condition’ 
F 1, 27 (P) 
NREMS        
Delta 365.5 ± 68.4  552.1  ± 109.1 † 328.2 ± 77.0 444.3 ± 112.3 † 1.35   (0.2547) 7.08   (0.0129) 0.30    (0.5886) 
Alpha  16.4 ± 2.6 20.3 ± 4.1 20.7 ± 2.6 25.0 ± 3.9 2.70   (0.1117) 1.09   (0.3057) 0.02    (0.8778) 
Sigma 12.3 ± 2.9 10.3 ± 2.0 13.9 ± 2,2 12.2 ± 2.1  2.87   (0.1020) 1.38   (0.2496) 0.00    (0.9543) 
Beta 2.3 ± 0.1 2.2 ± 0.2 3.1 ± 0.3 2.7 ± 0.3  5.56   (0.0259) 1.52   (0.2290) 0.24    (0.6253) 
        
REMS        
Delta 47.6 ± 8.6 59.9  ± 12.2  56.5 ± 10.9 65.1 ± 12.8  1.90    (0.1797) 3.13    (0.0883) 0.21    (0.6538) 
Alpha  7.6 ± 1.3 6.8 ± 0.8 10.5 ± 2.1 9.1 ± 1.6 1.84    (0.1868) 0.24    (0.6260) 0.01    (0.9277) 
Sigma 3.1 ± 0.3 3.4 ± 0.4 4.5 ± 0.6 4.2 ± 0.5 4.53    (0.0402) 0.02    (0.8809) 0.28    (0.5994) 
Beta 2.2 ± 0.1 ‡ 2.2 ± 0.2  3.7 ± 0.6 3.2 ± 0.5  7.46    (0.0110) 0.09    (0.7642) 0.26    (0.6147) 
 
Values represent whole night NREM and REM power spectra (μV
2
/0.25 Hz). Values show mean power ± SEM for a two way ANOVA with main 
factor ‘group’ and ‘condition’ and their interaction for ten IH patients and healthy controls. † p< 0.03 (paired, two-tailed t-test within group); ‡ p< 
0.05 (paired, two-tailed t-test between groups). 
Delta (0.75-4.5 Hz), Αlpha (8-12 Hz), Sigma (11.25-15 Hz), Βeta (15-20 Hz). 
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Discussion  
 
This is the first study performing a controlled sleep deprivation protocol in 
IH patients to challenge sleep-wake regulation. It is furthermore the first time in 
IH to report electroencephalographic data across night and day in the same 
individuals, in comparison to individually age- and sex-matched controls. 
 
We found no profound qualitative and quantitative differences in baseline- 
and recovery sleep in visually scored sleep variables. With this finding, we 
support the conclusion of a recent study that disrupted nocturnal sleep is 
infrequently observed in patients with IH (Takei et al., 2012). Nevertheless, in all 
vigilant states patients with IH had lower β-EEG power than controls. Intriguingly, 
there was no difference present in whole night spectral power between the 
groups, independent of night. Differences were present in higher frequencies, 
including θ-, α-, σ- and β-ranges to various degrees. IH is a disease with distinct 
characteristics when compared to other sleep disorders. For example, patients 
with narcolepsy have a deficiency in the hypocretin system of the lateral 
hypothalamus (Nishino et al., 2000; Kanbayashi et al., 2002; Anderson et al., 
2007). Furthermore, these patients experience disturbed NREMS-REMS patterns 
and strong sleep fragmentation, which underlies their non restorative sleep 
(Khatami et al., 2007; Khatami et al., 2008). Daytime sleepiness is the only 
common symptom in patients with IH and patients with narcolepsy. Another sleep 
disorder is insomnia which is defined by long sleep latency, frequent nocturnal 
awakenings, prolonged periods of wakefulness during a sleep episode, or 
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frequent transient arousals (Roth, 2007). It was shown that patients with 
insomnia have increased -activity in NREM sleep (Perlis et al., 2001; Bonnet 
and Arand, 2010). These findings suggest that insomnia is a disorder in which 
the arousal system is hyperactive (Bonnet and Arand, 2010). It is possible that 
the simultaneous, inappropriate activity of wake- and sleep-promoting systems in 
patients with insomnia underlie their inability to fall asleep. In contrast, patients 
with IH have a long and undisturbed nocturnal sleep. Despite this fact, patients 
with IH are sleepy during the day. Our study showed reduced β-power in patients 
with IH when compared to healthy controls.  
Similarly to patients with IH, patients with chronic fatigue syndrome (CFS) 
also suffer from unexplained persisting daytime sleepiness, and show 
significantly lower power in σ- and β-frequencies in sleep stage 2, SWS and 
REMS when compared to healthy controls (Decker et al., 2009). Although sleep 
architecture in patients with CFS does not differ from healthy controls (Majer et 
al., 2007), it was proposed that impaired sleep homeostasis contributes to the 
symptoms of CFS, because patients showed a blunted SWA response compared 
to controls to a 4-hour delay in bedtime (Armitage et al., 2007). Our study 
revealed no evidence that sleep homeostasis is impaired in patients with IH. 
 
Regarding the subjective data, IH patients had higher state anxiety than 
controls at 8 p.m., and a similar score at 8 a.m. in the morning after the night 
without sleep. In contrast, controls had a significantly lower score at baseline 
compared to IH; this score increased from the first to the second day to the same 
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level as IH. This result is in accordance with a study reporting higher anxiety 
(Hospital Anxiety and Depression rating scale, HAD) in IH than in controls. In the 
same study, IH and controls had to fill in a 5 point tiredness score (Vernet et al., 
2010). The patients were on a higher level during the whole day, a fact we could 
also show with the KSS. 
Performance on PVT is a measure of the sustained attention (Drummond 
et al., 2005). This task was not been previously applied to patients with IH. The 
results show reduced performance in the patient group. In general, it can be 
stated that sleep deprivation impaired performance in IH and controls in a similar 
manner, but on different levels. 
Biochemical markers showed similar evolution in both groups. Thus, we 
conclude that the circadian regulation of melatonin and cortisol secretion is intact 
in patients with IH. However, our data do not permit the definite conclusion that 
patients with IH have normal circadian rhythms, because we did not perform an 
experiment in the absence of any time information. 
 
In comparison with previous studies perfomed in patients with IH, our 
results show different findings. First, we did not find decreased SWA in IH 
compared to controls, as suggested by Sforza et al. (2000). Thus, our data to not 
support the idea of a changed build-up of the homeostatic process. We cannot 
rule out that the effect they observed was confounded by extended sleep 
duration in the patients prior to the sleep study, because sleep duration was not 
controlled for. Second, in contrast to Bové et al. (1994), we did not find a 
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difference in σ-power between patients with IH and healthy controls. In our study, 
we did not find a significant difference in σ-power, if anything σ-power tended to 
be lower in IH patients compared to controls. Again, the difference could have 
been caused by different sleep duration prior to the study night, since Bové et al. 
did not control for sleep length before their experimental recordings (Bove et al., 
1994). This is an important aspect, because reduced sleep pressure such as 
after naps increases σ-power, whereas sleep deprivation decreases σ-power 
(Dijk et al., 1993; Knoblauch et al., 2003). Thus, differences in prior sleep 
duration could have biased the previous results. Third, REMS latency showed a 
difference between the groups. Patients with IH showed a prolongation of the 
REMS latency from baseline to recovery night, weheras the opposite was found 
in the controls. The REMS latency was significantly longer in patients with IH 
when compared to healthy controls. Regarding the previously mentioned study, 
which found an increased REM density in REMS in IH compared to controls 
(Vankova et al., 2001), we did not analyse this variable and can, therefore, not 
compare the respective findings. Forth, salivary melatonin and cortisol 
concentrations revealed a normal secretion pattern over 24 hours and no 
difference between the groups. Therefore, we find no evidence to claim that IH 
have a misaligned circadian rhythm. A possible reason for the discrepancy to the 
study, in which a delayed secretion of both hormones was found (Nevsimalova et 
al., 2000) could lie in the control of habitual sleep episodes. Nevsimalova et 
al.did not control for regular wake-sleep schedule, nor for time of day when the 
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subjects went to bed. The observed delay in hormone secretion could be biased 
by late awakenings and late bed times. 
 
A possible imbalance in neurotransmitter systems, including the 
ascending arousal system (AAS), could underlie problems in vigilance. The 
reciprocal activities and interactions of wake-active and sleep-active cell groups 
determine the alternation between wakefulness and sleep (Saper et al., 2005). 
We assume that cholinergic cells, originating in the upper pons and the basal 
forebrain, and monoaminergic cells, originating from the brainstem, discharge 
mainly during behavioral arousal (Hallanger et al., 1987; Saper et al., 2011) to 
maintain wakefulness. The sleep promoting neurons originate mainly in the 
ventral preoptic area (VLPO), and are active during sleep by inhibiting, via 
GABA-ergic neurons, wake promoting regions such as the locus coeruleus (LC), 
tuberomammillary nucleus (TMN), and raphe nucleus (RN) (Saper et al., 2005). 
Reduced activity of these nuclei could underlie the increased sleepiness in 
patients with IH. Another explanation could be that the VLPO is hyperactive and 
attenuates the wake-active cell groups during wakefulness. Taken together, the 
EDS can either occur because of a decreased function of the AAS, or due to a 
hyperactivity of the VLPO. This hyperactivity in turn, suppresses AAS regions 
such as the LC, MTN and RN so strongly that a state transition to wake only 
occurs with effort which leads to sleep inertia in IH. 
We suggest that the phenotype of these dysregulated mechanisms in IH is 
EDS. To treat patients with EDS, a combination of behavioral and 
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pharmacological therapies are used. Today, mainly two drugs are administered 
to IH, namely, antidepressants and modafinil (Schwartz, 2004; Ballon and Feifel, 
2006). Currently used antidepressants inhibit reuptake of monoamines, which are 
the most prevalent neurotransmitter in the AAS and innervate the cerebral cortex 
for maintaining arousal. The site of action of modafinil is still unclear, but it leads 
to a reduction in EDS in IH (Gerrard and Malcolm, 2007). Authors suggest that 
modafinil blocks the reuptake of noradrenalin by the noradrenergic terminals on 
sleep-promoting neurons from the VLPO (Gallopin et al., 2004). An imaging 
study suggested that administration of modafinil increased extracellular DA and 
occupied DA transporters (Volkow et al., 2009). Therefore, it is likely that 
modafinil promotes dopaminergic neurotransmission. 
 
Conclusions  
The present study elaborated on the effect of 40 hours of wakefulness on 
sleep and waking EEG, and performance in patients with IH and matched 
controls. The major findings of this project are: (1) patients with IH have similar 
sleep variables as controls in baseline and recovery sleep; (2) patients with IH 
have a decreased high frequency EEG power, independently of vigilance state; 
(3) patients with IH have reduced performance during prolonged wakefulness; 
and (4) patients with IH have no change in salivary melatonin and cortisol 
concentration when compared to healthy controls. 
With our findings we have no evidence for impaired sleep homeostatic and 
circadian processes in patients with IH. We rather conclude that these patients 
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suffer from deficient brain arousal that could be a sign of reduced monoaminergic 
activity. 
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Chapter 4 
 
4.1  Discussion 
In this thesis, the effect of extended wakefulness was investigated with respect to 
changes in receptor availability in healthy subjects (project I), and in view of 
objective markers in spectral power in sleep and waking EEG in patients with IH 
(project II). 
 
In the following sections, our findings will be discussed and contextualized within 
current research. 
 
Metabotropic glutamate receptor subtype 5 – mGluR5 
In the first project, we quantified the availability of mGluR5 in the human brain 
using positron emission tomography (PET). The ligand 11C-ABP688 binds 
selectively to this receptor. Twenty-two healthy men participated in a two week, 
randomized crossover study. In one week, participants performed a PET scan 
after 9h of wakefulness, whereas in the other week the PET scan took place after 
they were kept awake for one night (i.e., after 32h of wakefulness). 
 
We found that cerebral mGluR5 availability has increased in the healthy human 
brain after a single night without sleep, indicating that mGluR5 contributes to the 
effects of sleep deprivation. Out of 13 volumes of interest (VOI) we analyzed, six 
regions showed a Bonferroni-corrected significant increase in receptor availability 
after prolonged wakefulness.  These regions were the anterior cingulate cortex, 
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insula, medial temporal lobe, parahippocampal gyrus, striatum, and amygdala. 
This increase was positively correlated with the subjectively rated increased 
sleepiness.  
 
Forty years ago, it was postulated that the homeostatic process underlying sleep 
regulation builds up during wakefulness and dissipates during sleep (Borbély, 
1982). However, the molecular and cellular mechanisms of the homeostatic 
process are unknown. The recently postulated synaptic homeostasis hypothesis 
is a conceptual framework that takes the two-process model of sleep-wake 
regulation, and the cellular properties into account (Tononi and Cirelli, 2006). 
According to this hypothesis, the number of synapses is upscaled during 
wakefulness and downscaled during sleep, in a use-dependant manner. A study 
in rats showed that in cortex and hippocampus GluR1-containing AMPA receptor 
(AMPAR) levels were high during wakefulness, and low during sleep (Vyazovskiy 
et al., 2008). Similarly, the phosphorylation of AMPAR was higher after 
wakefulness than after sleep in these rats. The authors postulate that with this 
up- and down-scaling, which goes in line with the phosphorylation and 
dephosphorylation of receptors in accordance to wakefulness and sleep, an 
overall balance of synaptic strength is preserved (Vyazovskiy et al., 2008). Our 
findings are consistent with the assumption of the synaptic homeostasis 
hypothesis during wakefulness. We observed that extended waking increased 
the global mGluR5 availability in the human brain. Similar findings were 
published by another group that studied adenosine A1 receptor (A1AR) binding 
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potential after sleep deprivation (Elmenhorst et al., 2007). These authors found 
that prolonged hours awake increased the binding potential of A1AR. They 
suggested that A1AR expression contributes to homeostatic sleep regulation. Our 
findings may also reflect synaptic potentiation: an increase in receptor density 
would lead to an increase in the strength of signal transmission between 
dendrites and axons. To corraborate a role for mGluR5 in sleep homeostasis, 
mGluR5 availability needs to be quantified after recovery sleep to show that it 
returns to the baseline level.  
 
A sleep deprivation study in three inbred mouse strains showed that Homer1a is 
overexpressed in a genotype-dependant manner. This overexpression was 
observed in the cortex, caudate and hippocampus (Maret et al., 2007). This 
finding is of interest, since different studies showed a close interaction between 
mGluR5 and Homer1a (Ango et al., 2000; Kammermeier and Worley, 2007; 
Bertaso et al., 2010; Tronson et al., 2010). The main consequence of mGluR5 
activation is the release of calcium from the postsynaptic intracellular calcium 
storage. Homer1a acts as an adaptor; it is an activity-dependent negative domain 
that regulates the scaffolding and signaling capabilities of the long Homer forms, 
and reduces glutamate-induced intracellular calcium release via the uncoupling 
of inositoltriphosphat (IP3) (Xiao et al., 2000; Kammermeier and Worley, 2007; 
Worley et al., 2007). It was shown that Homer1a expression alters mGluR 
signaling, even though large changes in mGluR organization are not seen 
(Kammermeier and Worley, 2007). Therefore, the plastic change of mGluR5 may 
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represent a viable mechanism to finetune synaptic strength on a short-term 
basis. Homer1a was proposed as a core molecular marker of sleep loss (Maret 
et al., 2007). Homer1a prevents the formation of the second messenger IP3 after 
activation of mGluR5 and reduces calcium release from intracellular storage. 
Moreover mGluR5 is involved in LTD. The increase in receptor availability after 
prolonged wakefulness could be a signal for a stronger downscaling of synapses 
during recovery sleep. However, to corroborate the underlying mechanism of 
these dynamic processes, further studies are needed. 
 
Various nervous system pathologies have been implicated with deregulated 
amounts of mGluR5. This receptor family provides a promising target to treat in 
the future psychiatric and neurological disorders, including schizophrenia, 
anxiety, fragile X syndrome, substance abuse, and drug withdrawal (Gasparini et 
al., 2008a; Niswender and Conn, 2010; Nagahara and Tuszynski, 2011). One 
study in depressed patients showed decreased mGluR5 availability in various 
cortical and subcortical brain regions when compared to healthy controls 
(Deschwanden et al., 2011). We found in healthy subjects increased availability 
of mGluR5 after prolonged wakefulness; this indicates that this receptor may be 
involved in the potent antidepressant effect of ‘wake therapy’ in patients with 
major depressive disorder. It is well established that sleep deprivation provides 
robust and rapid full clinical relief in many patients suffering from major 
depression (Bunney and Bunney, 2011). A possible underlying mechanism could 
be that increased receptor availability after sleep loss can lead to increased or 
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prolonged neuronal signaling. In contrast to available antidepressants, which 
take 2 to 3 weeks to exert an effect, our findings are of interest because of the 
fast response of mGluR5 availability.  
Another point to discuss is the relatively small, 4% to 5% increase in mGluR5 
availability from sleep control to sleep deprived condition. Although small, this 
increase is highly significant and reliable because of intraindividual normalization 
to cerebellum mGluR5 levels. We used this method to control for between-
subject variability, to reduce the standard deviation, and to increase the signal-to-
noise ratio. Because the mGluR5 is a G-coupled receptor, it amplifies 
downstream signaling in an exponential manner (Ross, 1989). Therefore, a 
change of roughly 5% in G-coupled receptor availability, in 21 healthy volunteers, 
is not only significant from a statistical point of view, but most likely also 
demonstrates a relevant physiological difference. 
The first evidence for increased cerebral mGluR5 availability after extended 
wakefulness was revealed with the present, in vivo molecular imaging study in 
healthy human volunteers. After a single night without sleep, binding of the non-
competitive ligand 11C-ABP688 was significantly increased on a global level, and 
in distinct brain regions which were previously shown to reflect physiological 
changes after sleep deprivation (Dang-Vu et al., 2010). 
 
Idiopathic hypersomnia - IH 
In the second project, we performed the first sleep deprivation study in patients 
with IH and their age- and sex-matched controls. With this protocol, we could 
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examine the response of patients with IH to prolonged hours of wakefulness on 
subjective and objective measures in comparison to healthy controls.  
 
We found similar sleep architecture in IH compared to controls. Power spectral 
analysis revealed the characteristic δ-decay during the first four NREMS 
episodes in both patients and controls, indicating normal function of the 
homeostatic process. High frequencies were significantly reduced in patients 
compared to controls. This reduced power was present in all three vigilance 
states, and possibly represents a characteristic marker in the EEG of patients 
with IH. During wakefulness, lower EEG power was present in all analyzed 
frequency bands. The evolution of melatonin and cortisol concentration in saliva 
during the 40h wakefulness showed a nearly congruent shape with no difference 
in timing and amplitude.  
 
Previous studies in patients with IH showed reduced SWA and an increased 
sleep spindle density when compared to healthy controls, while the time course 
of the homeostatic decay during sleep was not affected (Bove et al., 1994; Sforza 
et al., 2000). Our results did not corroborate these findings. By contrast, we 
found a similar amount of SWA in baseline and recovery sleep in IH and controls. 
A further result, which is not in line with previous findings, is the secretion rate of 
melatonin and cortisol. The published study found a reduced melatonin and a 
delayed cortisol secretion in IH compared to controls (Nevsimalova et al., 2000). 
In contrast, we found similar melatonin and cortisol concentration in saliva in 
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patients with IH compared to controls. A possible confounder is the habitual 
sleep-wake time, which was not controlled for by these the authors. A delayed 
cortisol secretion could be a consequence of late awakenings. A study performed 
in insomnia patients showed that they had decreased melatonin secretion and 
increased cortisol secretion at night (Bonnet and Arand, 2010). The only valid 
experiment to observe circadian shifts would be a free running study where the 
subjects would live for several days without any light and time cues. Such data 
could provide a valid statement about changes in circadian rhythmicity. With 
respect to patients with IH, another imaging study with insomnia patients 
revealed that they had higher global cerebral glucose metabolism during 
wakefulness and sleep, and further, a smaller decline in relative metabolism from 
wakefulness to sleep state in wake promoting regions. Therefore, they conclude 
that the higher brain metabolism could be associated with the difficulty of falling 
asleep. This could be interpreted as a failure in the arousal system to decline 
from the transition of wakefulness to sleep (Nofzinger et al., 2004). A future 
imaging study in patients with IH could help to clarify whether they have a 
reduced brain metabolism, and therefore would lead to EDS. An EEG study in 
CFS patients showed lower power in all frequencies analyzed (Decker et al., 
2009). By analyzing similar frequency bands in our study, we observed the same 
findings. We found that our patients had, in all analyzed frequency bands, lower 
power compared to controls. These results, spurred the idea of a diminished 
arousal system to keep these patients awake. 
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Sleep-wake regulation is influenced by neurotransmitter systems and the AAS. It 
is possible that patients with IH have a lower neurotransmitter tone, which would 
lead to an inappropriate suppression of the VLPO by the wake promoting regions 
of the AAS, namely, the LC, TMN, and RN (Saper et al., 2005).  
The VLPO neurons, which are GABA-ergic, project to the same wake-promoting 
regions and inhibit them. We found sleep variables in IH patients that are similar 
to controls, and suggest that the sleep GABA-promoting system is intact. Since 
the regions of the ventral pathway of the AAS are monoaminergic, it is probable 
that IH patients have a dysregulated monoaminergic neurotransmission. 
The question arises whether a link between endogenous DA and sleepiness 
exists. Mean firing rates of dopaminergic neurons in the substantia nigra and the 
ventral tegmental area have no profound change over the sleep-wake cycle in 
rats (Miller et al., 1983). Since others have found a rhythmicity of DA 
concentration in hypothalamus, medial prefrontal cortex, and nucleus accumbens 
(Eriksson et al., 1980; Lena et al., 2005), it is rather believed that the DA 
secretion pattern underlies a circadian modulation. Five DA G-protein coupled 
receptor families are separated and are grouped in D1-like family or D2-like 
familiy. D1-like family, containing D1R and D5R, activates adenylate cyclase (AC) 
which leads to an increase in intracellular cyclic adenosine monophosphate 
(cAMP). In contrast, the D2-like family, containing D2, D3 and D4, leads to an 
inhibition of the formation of cAMP by inhibiting the enzym AC (Neves et al., 
2002). DA receptors are mainly located in the cerebral cortex, the limbic system, 
hypothalamus, and striatum. A study, published 30 years ago, showed 
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decreased DA concentration in cerebrospinal fluid in patients with IH (Montplaisir 
et al., 1982). Furthermore, a human PET study found a decreased tracer binding 
to D2/3 receptors after sleep loss (Volkow et al., 2008). The authors interpreted 
this finding to reflect increased endogenous DA levels after prolonged 
wakefulness. The changes were associated with higher sleepiness and fatigue 
after sleep loss. Nevertheless, a follow-up study of the same research group 
showed that endogenous DA was not increased but D2 receptor density was 
decreased after sleep loss in healthy volunteers (Volkow et al., 2012). By 
contrast, preliminary data in seven IH patients suggest increased DA receptor 
availability by using PET imaging. This increase was present in the putamen and 
nucleus caudatus (Bassetti et al., 2009). This finding may be consistent with 
reduced endogenous DA signalling.  
Dopamine-enhancing drugs increase wakefulness by blocking DA transporters. 
Modafinil is suggested to stimulate the release of DA from the presynapse 
leading to an enhanced DA tone, and a prolonged DA mediated synaptic 
transmission (Nishino and Mignot, 2005). Others state that Modafinil blocks the 
reuptake of noradrenalin (NA) by the noradrenergic terminals on sleep-promoting 
neurons from the VLPO (Gallopin et al., 2004). It is most likely that DA and NA 
play a role in promoting both cortical activation and behavioral arousal of waking 
and, thus, are useful in treating hypersomnolence (Nishino and Mignot, 1997). 
 
Little is known about objective measures in patients with IH. To our knowledge, 
we performed the first sleep deprivation study in IH patients with additional 
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daytime recording in the same subjects. The spectral power in high frequencies 
was reduced in patients, independent of vigilant state. We suggest that rather 
than sleep, it is the waking functions which are diminished in IH patients.  
 
mGluR5 and IH 
Taking the findings of the two studies together, two questions may be considered 
for future studies:  
1) Do patients with IH have higher mGluR5 levels than controls under basal 
condition? 
2) Does a potential competitive and selective mGluR5 antagonist decrease 
sleepiness in healthy controls and IH patients? 
 
With these two aspects, we would obtain a better understanding of whether 
subjective sleepiness and performance are associated with high basal mGluR5 
availability, and whether an antagonist could decrease the excessive sleepiness 
in patients by modulating the receptors downstream signaling. Whether an 
antagonist administered to healthy subjects can lead to an even more increased 
performance,  is subject of further interest.  
 
4.2  Concluding remarks 
From an evolutionary point of view, sleep is a universal phenomenon. All species 
studied to date show a sleep-like phenotype. It is thought that sleep in some way 
evolved to serve restoration. Because sleep is seen in all studied animals, it is 
suggested that it serves a crucial physiological function which, however, is still 
unknown. 
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Appendix 
 
I Supplementary information to chapter 1 
 
Methodology of Positron emission tomography (PET) 
 
PET is a non-invasive nuclear imaging method which enables the visualization of 
cellular function and molecular processes in the living organism under 
physiological and pathophysiological conditions. For example, using an 
appropriate radiotracer a so-called biodistribution study can be performed to 
study the occurrence or absence of a specific molecule or receptor in specific 
organs or tissue regions. 
 
Instable atoms which decay are referred to as radionuclides. Radionuclides used 
in PET scanning are isotopes emitting positrons (β+-decay) and typically have 
short half-live times (t1/2), such as carbon-11 (
11C; t1/2 = 20.4min), nitrogen-13 
(13N; t1/2 = 9.9min), oxygen-15 (
15O; t1/2 = 2.04min) or fluorine-18 (
18F; t1/2 = 
110min). These radionuclides, which are isotopes of the biologically ubiquitous 
elements, are incorporated either into compounds normally used by the body 
such as glucose, water or into molecules that bind to receptors. Such labeled 
compounds are known as radiotracers. Due to the short half-live time of the 
isotopes, the cyclotron for the production of these radiotracers must be in close 
proximity to the PET imaging facility. 
 
A big advantage of PET imaging is that only little tracer amounts of a given 
radiotracer have to be injected for appropriate detection efficiency. Therefore, no 
physiological effects are expected. After intravenous injection, the concentration 
of the radiotracer in tissue is measured by the PET scanner in a static manner. 
During the decay process, the radionuclide emits a positively charged positron 
(e+, positive β-decay). After traveling a short distance (in the range of few 
millimeters) it encounters an electron (e-) from the surrounding tissue. The 
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encounter annihilates both electron and positron resulting in the emission of a 
pair of γ-rays each of 511keV moving in approximately opposite direction. The 
image acquisition is based on the coincidence detection of the emitted γ–rays. 
Two detectors on the opposite side of the scanner reconstruct and produce an 
image with region specific density or activity of the target molecule. After image 
acquisition, attenuation correction is performed by applying mathematical 
algorithms. The reason for this correction is the differential attenuation of the 
photons by the tissue. Structures deep in the body are reconstructed as having 
falsely low tracer uptake. Contemporary PET/CT scanners estimate attenuation 
based on the CT scan acquired in the same imaging session.  
 
Even though PET is a non-invasive method it does involve exposure to ionizing 
radiation. The total dose of radiation is substantial, usually around 5-7mSv per 
PET scan. Nowadays, often a combined PET/CT scan is performed and the 
radiation exposure may increase up to 23-26mSv for a 70kg person. (The sievert 
(Sv) is the unit of dose equivalent radiation. It attempts to quantitatively evaluate 
the biological effects of ionizing radiation as opposed to the physical aspects, 
which are characterised by the absorbed does, measured in gray (Gy). The unit 
Gy measures the absorbed dose of radiation, absorbed by any material. In 
contrast, Sv measures the equivalent dose of radiation supposed to have a 
damaging effect equivalent to the same dose of γ rays) 
 
Compared with other non-invasive imaging techniques PET has a high sensitivity 
with moderate temporal and spatial resolution (Fig. I).  
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Figure I: A schema displaying the relationship between the spatial and temporal resolution in 
terms of their invasiveness for commonly used imaging tools. Axes represent logarithmic values 
(Tracey, 2008). 
  
3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-methyl-oxime (11C-ABP688) 
 
 
Figure II: Structure of 
11C-ABP688 (Ametamey et al., 2007).  
 
One of the most commonly used radionuclide is C11 since it can be incorporated 
into many molecules without significant effect on biological activity of the 
molecule and in addition, the short half life allows repeated injections in the same 
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subject and day. 11C-ABP688 was recently developed in collaboration between 
Novartis and the ETH Zürich and is the first radioligand for imaging the mGluR5 
in vivo. Radiosynthesis was performed as described by Ametamey et al. 
(Ametamey et al., 2007). 11C-ABP688 exhibits a high in vitro and in vivo affinity 
as well as a high specificity for mGluR5 and was found to have a saturation level 
of receptor binding (Ametamey et al., 2006). It binds to the allosteric site of the 
mGluR5. 
The key properties of a good radioligand for receptor imaging and for high quality 
PET images are high specific radioactivity (SA) to have negligible receptor 
occupancy by non-radioactive compound; the selectivity over other receptors 
depends upon both the affinity of the tracer as well as the quantity of non-specific 
binding. Ametamey et al. (Ametamey et al., 2006) reported that the specificity of 
11C-ABP688 binding was confirmed by blockade studies with M-MPEP an 
antagonist for mGluR5. Up to 80% specific binding was observed for the 
hippocampus and striatum, regions with known high mGluR5 densitiy. No 
blocking effects were observed in the cerebellum. The data suggest that 11C-
ABP688 has a favorable metabolic profile. 
Although the radiolabeled metabolites were not individually identified, the 
metabolite profile suggests a similar metabolic fate of 11C-ABP688 in both, 
rodents and humans (Ametamey et al., 2007). Animal studies in wild type mice 
and rats showed in ex vivo autoradiography the highest uptake in hippocampus, 
striatum and the cortex (Ametamey et al., 2006). Biodistribution study in humans 
by Treyer et al. (Treyer et al., 2008) proclaimed that mGluR5 is a promising 
ligand to study mGluR5 in humans because the brain uptake is high and the 
effective dose equivalent so low making serial examinations in the same subject 
feasible. 
 
In humans, the rich mGluR5 regions are the anterior cingulated cortex (ACC), 
medial temporal lobe, amygdale, caudate and putamen. Regions with little 
mGluR5 density are the cerebellum and the white matter. The highest uptake 
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was measured in the ACC with 5.45 ± 1.47 (arbitrary unit) and the lowest in 
cerebellum with 1.91 ± 0.32 (Ametamey et al., 2007). 
 
The observations that mGluR5 may play an important role in a wide range of 
mental disorders, such as anxiety disorders, depression etc. made it a target of 
high interest in psychiatry research. One study with depressed patients showed a 
decreased mGluR5 density compared with healthy control subjects 
(Deschwanden et al., 2011). Furthermore, this tracer may be used in the future to 
study and evaluate drug-induced receptor occupancy, as well as in detecting 
possible differences in brain mGluR5 receptor levels of different psychiatric 
disorders.  
 
Image acquisition and processing 
 
The volunteers were prepared with two antecubital vein catheters for tracer 
injection on one side and for blood sampling on the other side . 
Before PET scanning started a low-dose CT scan was acquired for correction of 
photon attenuation. The method used is a bolus-infusion (B/I) protocol. It is useful 
for fast receptor binding. During the first two minutes half of the radiotracer is 
injected via a bolus, while during the following 58 minutes the second half is 
infused continuously. Treyer et al. (2007) showed that after 40 minutes an 
equilibrium should be achieved which directly represents the distribution volume 
(Fig. III) of the mGluR5. Image acquisition was started a the same timepoint as 
the tracer injection. The injected doses of 11C-ABP688, measured in Bequerel 
(Bq) normally lied between 477-746 kBq/cc. Every minute during the first ten 
minutes and every five minutes in the following 50 minutes an image was 
acquired resulting in a static data set of 20 images. Blood samples were taken 
after 58 minutes for metabolite determination. An aliquot of the sample was 
measured in a y-counter. Due to the recent publication of Burger et al. (Burger et 
al., 2010) where they showed that with the B/I protocol early time points 
correspond to perfusion and later time points to the total distribution volume, we 
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decided to use the average over the late frames (45, 50, 55 minutes) to obtain 
the uptake pattern and as a representative value of the DV. 
 
 
 
Figure III: Normalized distribution volume of one subject. 
Top row images of control condition; bottom row images of sleep deprived condition. 
 
All calculations were performed using the dedicated software PMOD (PMOD 
Technologies) (Mikolajczyk et al., 1998). After averaging the images, rigid 
matching was used for the comparison of the images from the control and sleep 
deprived condition. Furthermore, the images needed to be transformed into a 
reference space (Montreal Neurological Institute, MNI) to make comparison 
between different individuals possible. In a next step, the whole brain activity was 
divided by the cerebellum activity (cerebellum is suggested to be a valuable 
reference region because of very low receptor binding). The cerebellum was 
encircled by hand for each person and overlaid with the PET image and divided 
by the cerebellum value. In addition, MRI was performed to exclude any cerebral 
pathologies. As a last step, volume of interest (VOI) analysis was performed. The 
VOI analysis was based on the standard VOIs defined by the automated 
anatomical labelling (AAL) template (Tzourio-Mazoyer et al., 2002). Figure V 
represents a template of two regions. 
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The VOIs were chosen according to literature and included: Superior medial 
frontal cortex, orbitofrontal cortex, anterior cingulat cortex, insula, middle 
temporal cortex, precuneus, striatum, amygdale, hippocampus, 
parahippocampus, thalamus and an average group value of all brain regions 
excluding the cerebellum for both hemispheres separate. 
 
To justify the findings two more variables needed to be generated. First, the time 
activity curve (TAC), to verify that in all subjects the equilibrium, was reached. 
Four regions were chosen: the putamen (left and right), frontal superior cortex, 
(left and right), thalamus (left and right) and the cerebellum as a whole. The 
resulting TACs confirmed in all regions and subjects a steady state in the second 
half of the scan (Fig. IV). 
 
 
Figure IV: Representative time activity curves of 
11
C-ABP688 uptake in a single subject. 
The curve displays the evolution of a bolus-infusion protocol. Each symbol represents a time 
point where a picture was taken. The first ten images have an interval of one minute whereas the 
following ten images have an in-between interval of five minutes. Relative high radioactivity 
uptake is observed in mGluR5 rich regions such as the anterior cingulated cortex (ACC), 
moderate binding in the thalamus and low uptake in the cerebellum. 
Solid line represents data from control condition whereas the dotted line represents data from 
sleep deprived condition. 
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Second, the standard uptake value (SUV) of cerebellum needed to be calculated 
to show that the intervention, in our case the sleep deprivation, had no effect on 
the receptor availability in the cerebellum. Otherwise, cerebellum could not be 
used as the reference region for the normalisation. The radioactivity 
concentrations of the cerebellum were decay-corrected and normalized to 
injected radioactivity dose and body weight. The results revealed no difference in 
the cerebellum mGluR5 density between the two conditions. 
 
 
Figure V: Region of interest according to PMOD atlas. 
Black: caudate; Grey: putamen; Images in axial, sagittal and coronal view; R: right side; L: left 
side; A: Anterior; P: Posterior; Grey: Putamen right hemisphere; White: Caudate right 
hemisphere. 
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II Supplementary information to chapter 2 
 
Study design of the mGluR5 project 
 
 
 
All subjects participated in a two weeks randomized and cross-over study 
protocol. Sleep in adaptation (AD), baseline (BL) and recovery (REC) night was 
monitored with polysomnographically recordings. A positron emission 
tomography (PET) was measured at 4 pm after 9 or 33 hours awake 
respectively. During the 40 hours of prolonged wakefulness and during the 
second day during the control week different cognitive tasks and questionnaires 
needed to be filled in. DRM: Deese-Roedinger-McDermott memory task; Story: 
listening to a story and recall it immediately and at a delayed time point; RNG: 
Random Number Generation task; KSS: Karolinska Sleepiness Scale; POMS: 
Profile Of Mood State; EEG: 8 minutes electroencephalogram during 
wakefulness.   
 
 
 
 
 
Waking EEG, 
PVT, Saliva 
8                 11                 14                 17                 20                 23 Clock time 
Sleep        
deprivation 
Control AD BL 1 BL 2 
BL 1 REC 
P
E
T 
  Task  DRMlear
n 
 Storyimm
. 
 RNG  DRMrecog. Storydelaye
d 
 KSS  POMS 
PET 
EEG 
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III Supplementary information to chapter 3 
 
Study design of the idiopathic hypersomnia project 
 
 
 
Idiopathic hypersomnia patients and healthy matched controls participated in a 
study design including a period of 40 hours without sleep. Sleep in adaptation 
(AD), baseline (BL) and recovery (REC) night was monitored by 
polysomnographically recordings. During the period of prolonged wakefulness 
patients and controls filled in questionnaires, performed tasks and EEG were 
measured in 3-hour intervals. KSS: Karolinska Sleepiness Scale; PVT: 
Psychomotor Vigilance task; EEG: 8-minutes electroencephalogram recording 
during wakefulness. 
 
 
 
 
 
 
 
 
 
Clock time 
Hours awake 
AD BL  REC Prolonged wakefulness (40h)   
at 3-h intervals: KSS, PVT and waking EEG 
8    11    14    17    20    23    2    5    8     11    14    17    20    
23 
0    3    6    9    12    15    18    21    24    27    30    33    36    39 
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